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INTRODUCTION

The multinational effort to sequence the human genome
was one of the most ambitious scientific undertakings in
history and has been compared to the Apollo manned space
program, the Lewis and Clark expedition, and the Manhattan
Project.1 When completed, the Human Genome Project (HGP),
which spanned fifteen years2 and involved over a thousand
scientists worldwide, was heralded by President Bill Clinton as
“an epoch-making triumph of science and reason.”3 It led to the
publication of the first complete human DNA sequence and has
resulted in major advances in biochemistry, bioinformatics, and
genetics.4 The project also generated vast quantities of data
about the genetic make-up of humans and other organisms,
which reside in public databases that are available to any
researcher in the world, creating what I refer to as the “genome
commons.”5 But, in some respects, even more remarkable than
1. E.g., ARTHUR M. LESK, INTRODUCTION TO GENOMICS 22 (2007);
FRANCIS S. COLLINS, THE LANGUAGE OF LIFE 2 (2010); VICTOR K. MCELHENY,
DRAWING THE MAP OF LIFE – INSIDE THE HUMAN GENOME PROJECT at ix
(2010); James D. Watson, The Human Genome Project: Past, Present and
Future, 248 SCIENCE 44, 44 (1990).
2. Planning for the HGP began in 1988 and is generally agreed to have
concluded in 2002, though work continues to refine the human genomic map.
See, e.g., Jeffrey M. Kidd et al., Mapping and Sequencing of Structural
Variation from Eight Human Genomes, 453 NATURE 56 (2008); Watson, supra
note 1, at 46; Major Events in the U.S. Human Genome Project and Related
Projects,
U.S.
DEPARTMENT
OF
ENERGY
GENOME
PROGRAM,
http://www.ornl.gov/sci/techresources/Human_Genome/project/timeline.shtml
(last visited Oct. 28, 2010).
3. Reading the Book of Life: White House Remarks on Decoding of
Genome, N.Y. TIMES, June 27, 2000, at F8.
4. See generally Francis Collins, Opinion: Has the Revolution Arrived?,
464 NATURE 674 (2010) (describing the “profound impact on scientific
progress” achieved by the HGP); International Human Genome Sequencing
Consortium, Initial Sequencing and Analysis of the Human Genome, 409
NATURE 860, 911–13 (2001) [hereinafter HGP Initial Paper] (discussing the
impact the HGP has had on scientists’ ability to find disease genes and drug
targets).
5. Jorge L. Contreras, Prepublication Data Release, Latency, and Genome
Commons, 329 SCIENCE 393, 393 (2010) [hereinafter Contreras, Prepublication
Data Release]. The term “commons” derives from the traditional designation of
shared physical resources such as fields, pastures and forests, but has more
recently been applied to intangibles and information, including aggregations of
scientific data. See, e.g., Charlotte Hess & Elinor Ostrom, Introduction: An
Overview of the Knowledge Commons, in UNDERSTANDING KNOWLEDGE AS A
COMMONS: FROM THEORY TO PRACTICE 4, 12 (Charlotte Hess & Elinor Ostrom
eds., 2006) (discussing the evolution of the term “commons”); Michael J.
Madison, Brett M. Frischmann & Katherine J. Strandburg, Constructing
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the impressive quantity of data generated by the HGP is the
speed at which that data has been released to the public.
At a 1996 summit in Bermuda, still early in the HGP,
leaders of the scientific community agreed on a groundbreaking
set of principles requiring that all DNA sequence data be
released in publicly-accessible databases within twenty-four
hours after generation.6 These “Bermuda Principles”7
Commons in the Cultural Environment, 95 CORNELL L. REV. 657, 659 (2010)
[hereinafter Cultural Commons] (discussing the governance of cultural and
scientific knowledge “commons”); Jorge L. Contreras, Data Sharing, Latency
Variables and Science Commons, 25 BERKELEY TECH. L.J. (forthcoming 2010)
[hereinafter Contreras, Data Sharing] (discussing the challenges of creating
scientific knowledge commons).
6. Summary of Principles Agreed at the First International Strategy
Meeting on Human Genome Sequencing, U.S. DEPARTMENT OF ENERGY
GENOME
PROGRAM,
http://www.ornl.gov/sci/techresources/Human_Genome/research/bermuda.sht
ml (last visited Oct 28, 2010) [hereinafter Bermuda Principles] (reproducing
the original report by the Human Genome Organisation (HUGO)). The text of
the Bermuda Principles, as reported by the Human Genome Organisation
(HUGO), reads, in pertinent part, as follows:
Primary Genomic Sequence Should be in the Public Domain
It was agreed that all human genomic sequence information,
generated by centres funded for large-scale human sequencing,
should be freely available and in the public domain in order to
encourage research and development and to maximise its benefit to
society.
Primary Genomic Sequence Should be Rapidly Released
•
Sequence assemblies should be released as soon as possible;
in some centres, assemblies of greater than 1 Kb would be
released automatically on a daily basis.
•
Finished annotated sequence should be submitted
immediately to the public databases.
It was agreed that these principles should apply for all human
genomic sequence generated by large-scale sequencing centres,
funded for the public good, in order to prevent such centres
establishing a privileged position in the exploitation and control of
human sequence information.
The text of the Bermuda Principles contained in a recent National Research
Council report appears to reproduce an earlier, unapproved draft of the
Bermuda Principles that contains the apocryphal sentence “[i]t was also
agreed that patents should not be sought.” NATIONAL RESEARCH COUNCIL,
REAPING THE BENEFITS OF GENOMIC AND PROTEOMIC RESEARCH 57, box C
(2006) [hereinafter NRC – GENOMIC AND PROTEOMIC RESEARCH]. It is the
author’s understanding, based on conversations with attendees at the original
Bermuda meeting, that this sentence was deleted prior to final approval and
does not form part of the generally-accepted text of the Bermuda Principles.
Its significance, however, is discussed infra Section III.B.
7. These principles are referred to variously in the literature as the
Bermuda Principles, the Bermuda Agreement, the Bermuda Resolution, the
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contravened the typical practice in the sciences of making
experimental data available only after publication8 and were
praised by many including President Clinton, who urged “all
nations, scientists and corporations to adopt this policy and
honor its spirit.”9 The Bermuda Principles represent a
significant achievement of private ordering in shaping the
practices of an entire industry and establishing a global
knowledge resource for the advancement of science. They
continue to shape the data release practices of the genomics
research community and have established rapid pre-publication
data release as the norm in this and other fields.10 In this
Bermuda Rules, the Bermuda Protocol and the Bermuda Accord. For the sake
of consistency, I will use the term “Bermuda Principles” throughout this
paper.
8. Prior to the adoption of the Bermuda Principles (and to this day in
fields outside of genomics), the data release policies of most governmentfunded projects allowed researchers to retain their data privately until
publication of results or for some specified “exclusivity period”, usually in the
neighborhood of one year. See, e.g., NATIONAL ACADEMY OF SCIENCES,
ENSURING THE INTEGRITY, ACCESSIBILITY, AND STEWARDSHIP OF RESEARCH
DATA IN THE DIGITAL AGE 64 (2009) [hereinafter NAS – RESEARCH DATA]
(noting that NASA and the European Southern Observatory Administration
impose a 12-month proprietary periods and the U.S. National Optical
Astronomy Observatory imposes an 18-month proprietary period on the
release of data); NATIONAL RESEARCH COUNCIL, SHARING PUBLICATIONRELATED DATA AND MATERIALS: RESPONSIBILITIES OF AUTHORSHIP IN THE
LIFE SCIENCES 75 (2003) [hereinafter NRC – SHARING PUBLICATION-RELATED
DATA] (describing the one-year “hold allowance” on the deposition of
crystallography data into the Protein Data Bank); NATIONAL RESEARCH
COUNCIL, BITS OF POWER – ISSUES IN GLOBAL ACCESS TO SCIENTIFIC DATA
80–82 (1997) (describing data release policies of NASA and Global Change
Research Program); J.H. Reichman & Paul F. Uhlir, A Contractually
Reconstructed Research Commons for Scientific Data in a Highly Protectionist
Intellectual Property Environment, 66 LAW & CONTEMP. PROBS. 315, 335
(2003) (“[i]n most cases, publication of research results marks the point at
which data produced by government-funded investigators should become
generally available”).
9. JAMES SHREEVE, THE GENOME WAR 322 (2004) (quoting President
Clinton).
10. See, e.g., Collins, supra note 4, at 675 (referring to the “radical ethic of
immediate data deposit” adopted by the HGP as the current “norm for other
community research projects”); Jane Kaye et al., Data Sharing in Genomics –
Re-shaping Scientific Practice, 10 NATURE REV. GENETICS 331, 332 box 1
(2009) (“[t]hese policies have created a climate in which data sharing has
become the default, and [grant] applicants must demonstrate why their data
should be exempt from the requirement that it should be deposited for use by
other scientists”); Nikos Kyrpides, Fifteen Years of Microbial Genomics:
Meeting the Challenges and Fulfilling the Dream, 27 NATURE BIOTECHNOLOGY
627, 627 (2009) (“[o]ver time, as the substantial benefits of prepublication
release of genome data have been recognized, many funding agencies and most
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paper, I offer the first systematic analysis of the social, legal,
and political factors that led to the adoption of the Bermuda
Principles and the evolution of genomic data release policies
over the past two decades.
At the outset of the HGP, policy makers realized that it
was necessary to develop efficient systems for coordinating
activity among the geographically dispersed laboratories
working on the massive project. But project coordination was
not the only factor justifying the unorthodox rapid-release
requirement of the Bermuda Principles.11 Rather, this
revolutionary approach arose from the belief of several project
leaders, both scientists and policy makers, that rapid release of
the project’s genomic data was desirable for the advancement of
scientific discovery and the consequent improvement of human
health.12 Two distinct policy rationales thus emerged to support
the rapid data release principles of Bermuda: (1) project
coordination and (2) scientific advancement. Coupled with
these, however, was a third distinct policy rationale for rapid
data release: (3) minimizing encumbrances of DNA sequence
data by patents.13 While this policy objective was seldom stated
explicitly, it reflects a current that runs through many of the
early (and recent) debates regarding data release.
After the HGP completed its work, the rapid data release
principles adopted in Bermuda were exported to other projects
involving genomic and related technologies.14 Advances in
science and technology, however, together with increasingly
of the large sequencing centers now adhere to the rapid data release policy set
forth as the Bermuda Principles in 1996 and renewed in 2003”).
11. Though systems for sharing data among participating researchers
were used in large-scale scientific projects such as the Manhattan Project and
the NASA space launches, the release of data to the public was not a priority
in these projects.
12. See, e.g., HGP Initial Paper, supra note 4, at 864 (“[w]e believed that
scientific progress would be most rapidly advanced by immediate and free
availability of the human genome sequence. The explosion of scientific work
based on the publicly available sequence data in both academia and industry
has confirmed this judgment”).
13. By the late 1980s and the beginning of the HGP, there was already
heated debate in the United States regarding the patentability of genetic
material. See ROBERT COOK-DEEGAN, THE GENE WARS – SCIENCE, POLITICS,
AND THE HUMAN GENOME 308–11 (1994); MCELHENY, supra note 1, at 117.
The increasing trend toward patenting of genetic material alarmed many of
the leaders of the HGP. See infra note 92 and accompanying text.
14. See Kyrpides, supra note 10, at 627–28.
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complex ethical, legal, and technical issues, have complicated
the data release landscape and given rise to additional policy
considerations. Among these have been (4) the protection of
human subject data that resides in public databases (data
protection), and (5) the need for scientists generating large data
sets to publish their data before it is accessed and used by
others in order to facilitate their own career advancement and
grant funding (publication priority).15 The emergence and
recognition of these considerations has led to an evolution of
genomics data release policies. The bold pronouncements made
in Bermuda have given way to more nuanced approaches that
address differences in types of data and the goals of the projects
themselves, as well as the differing and sometimes divergent
requirements of data generators and data users.
Elinor Ostrom and her colleagues pioneered the analysis of
common
resource
structures,
whether
physical
or
informational, using an organizational theory tool known as the
Institutional Analysis and Development (IAD) framework,
work that earned her the 2009 Nobel Prize in Economics.16
More recently, Michael Madison, Brett Frischmann, and
Katherine Strandburg have undertaken a thorough reexamination of the IAD framework in relation to commons in
the “cultural environment,”17 seeking to combine the
functionalist IAD approach with metaphorical and narrative
accounts of commons formation.18 In this paper, I engage the
theoretical framework of Ostrom and Madison, Frischmann,
and Strandburg and elucidate both the structural and
15. Among the factors weighing most heavily against rapid data release is
the loss by data generators of any “head start” that they might otherwise have
had in preparing papers analyzing the released data. That is, under a rapid
data release structure, data generators must release their data very shortly
after it has been produced, giving competing researchers access to the data at
the same time as the scientists who generated it. See, e.g., Contreras, Data
Sharing, supra note 5 (observing that data retention strategies give the data
generator a head start with respect to analyzing the data). See generally infra
Section III.B.2 (discussing the process of publishing of results and the
requirements for making the underlying raw data publicly available).
16. Press Release, The Royal Swedish Academy of Sciences (Oct. 12,
2009),
available
at
http://nobelprize.org/nobel_prizes/economics/laureates/2009/press.html.
17. Cultural Commons, supra note 5, at 659. Madison, Frischmann and
Strandburg refer to aggregations of shared information as “cultural commons”
and include within their far-ranging analysis shared resource structures as
varied as patent pools, open source software, Wikipedia, the Associated Press,
and jamband fan communities. Id. at 660–63.
18. Id. at 671–74, 681–83.
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narrative elements of the unique developmental history of the
genome commons. The IAD methodology offers a systematic
means for examining the characteristics of a commons
structure: those of the common resource, the “action arena” in
which stakeholders interact with the commons and the
resulting patterns of interaction.19 Each of these broad areas is
subdivided into further analytical components so that the
common resource, for example, is assessed with respect to its
bio-physical characteristics, the attributes of the relevant
community, and its applicable “rules in use.”20 The application
of the IAD framework analysis results in a deeper
understanding of the factors that should be considered when
structuring or evaluating an information commons.
Consistent with the IAD methodology, I describe in Part
II.A the characteristics of the genome commons, including both
genomic data and the databases in which it is housed. In Part
II.B, I identify and discuss the various stakeholder
communities involved in the development and use of the
genome commons and their predisposition toward the five
principal policy considerations noted above. In Part III, I trace
the development of genomic data release policies in the United
States, beginning with the HGP and the Bermuda Principles
and concluding with current and planned policies both in
government-funded and private projects. In Part IV, I analyze
the impact of the five policy considerations identified above on
the evolving genome commons landscape, particularly in view
of the requirements and objectives of the relevant stakeholder
communities. I conclude with a number of observations
regarding the applicability of these findings to the design of
commons in the sciences, generally, and to the future direction
of the genome commons.

19. See Elinor Ostrom & Charlotte Hess, A Framework for Analyzing the
Knowledge Commons, in UNDERSTANDING KNOWLEDGE AS A COMMONS: FROM
THEORY TO PRACTICE 41, 44–45 (Charlotte Hess & Elinor Ostrom eds., 2006).
20. Id. at 45–53.

121_CONTRERAS.DOCX (DO NOT DELETE)

2011]

4/4/2011 8:14 AM

BERMUDA’S LEGACY

69

II. ATTRIBUTES OF THE GENOME COMMONS
A. GENES AND GENOMES
1. Building Blocks21
Deoxyribonucleic acid (DNA) is a chemical substance that
exists in almost every living organism. Each DNA molecule is
composed of four basic building blocks or nucleotides: adenine
(A), thymine (T), guanine (G) and cytosine (C). These
nucleotides form long strings of linked pairs (A-T and G-C) that
are twisted in a ladder-like chain: the famous “double-helix”
first described by James Watson and Francis Crick in 1953.
Each rung of this ladder is referred to as a “base pair”, and the
full complement of DNA found within an organism is its
“genome”. The genome of simple organisms such as the E. coli
bacterium contains approximately five million base pairs, that
of the fruit fly Drosophila melanogaster contains approximately
160 million base pairs, and that of Homo sapiens contains
approximately 3.2 billion base pairs.
The double-helical strands of DNA that exist within an
organism’s cells are typically bound into discrete units called
“chromosomes” (each human carries twenty-three pairs of
chromosomes). The DNA on each chromosome is divided into
smaller “genes,” ranging in size from as few as one hundred to
more than two million base pairs. It is currently estimated that
humans each possess approximately 25,000 genes, which are
generally regarded as the basic functional units of DNA. An
organism’s genes serve many functions. They are responsible
for the inheritance of traits from one generation to the next,
and they encode the many proteins responsible for the
biochemical functions within the cell. Each human genome is
approximately 99.5 percent identical, but very small differences
are responsible for the great variability in human physical and
physiological traits. The observable characteristics of an
individual, including physical, physiological, behavioral, and
demographic characteristics, are referred to as that individual’s
“phenotype.” One of the principal goals of genetic science has
21. This Section contains a basic explanation of the scientific terminology
and concepts used throughout this paper. Most of this information can be
found in any modern biology textbook. In some cases, I have simplified the
discussion of complex scientific concepts for the general reader. See generally
LESK, supra note 1; MATTHEW RIDLEY, GENOME 6–10 (1999); WILLIAM S.
KLUG & MICHAEL R. CUMMINGS, ESSENTIALS OF GENETICS (3d ed. 1999).
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been to associate particular genes, genetic variations, or
“mutations” with phenotypic traits.
2. Medical Genetics
As early as 1902, scientists began to associate hereditary
diseases with genes passed down from parents to their
offspring. But while numerous conditions were associated with
patterns of inheritance, from relatively benign traits such as
albinism and hair color to debilitating ailments such as cystic
fibrosis, Down syndrome, and Huntington’s disease, it was not
until the 1970s that technology had advanced to a state
sufficient to enable scientists to identify the individual genes
responsible for these conditions. Even then, each of these
discoveries took years of painstaking work and a measure of
good luck to achieve. It was not until 1986 that a revolutionary
new process for copying DNA fragments called polymerase
chain reaction (PCR) enabled the large-scale, rapid sequencing
of DNA. The advent of PCR technology soon gave rise to
ambitious plans to sequence not only genes identified with
specific diseases, but the entire human genome.
3. The Human Genome Project22
The Human Genome Project was formally launched in
1990 as a joint project of the National Institutes of Health
(NIH)23 and the U.S. Department of Energy (DOE),24 with
22. The Human Genome Project, and particularly the race between the
publicly-funded HGP and Celera Genomics, has been the subject of numerous
popular and scholarly accounts. See generally SHREEVE, supra note 9; J. CRAIG
VENTER, A LIFE DECODED: MY GENOME, MY LIFE (2007); NRC – GENOMIC AND
PROTEOMIC RESEARCH, supra note 6, at 34–36; INSTITUTE OF MEDICINE &
NATIONAL RESEARCH COUNCIL, LARGE-SCALE BIOMEDICAL SCIENCE 31–40
(2003) [hereinafter LARGE-SCALE SCIENCE]; HGP Initial Paper, supra note 4,
at 862–63. The early days of the HGP are extensively chronicled by Robert
Cook-Deegan in COOK-DEEGAN, supra note 13.
23. The National Institutes of Health (NIH) formed the National Center
for Human Genome Research (NCHGR) in 1989, under the direction of James
Watson, to carry out its component of the HGP. In 1997, the Department of
Health and Human Services elevated NCHGR to the status of a full “institute”
within the NIH system, forming the National Human Genome Research
Institute (NHGRI). About NHGRI: A Brief History and Timeline, NATIONAL
HUMAN GENOME RESEARCH INSTITUTE, http://www.genome.gov/10001763 (last
visited Oct. 28, 2010).
24. DOE’s interest in a genome sequencing project arose from its work on
genetic mutations among atomic bomb survivors. See COOK-DEEGAN, supra
note 13, at 93–95. DOE was also the overseer of the GenBank DNA sequence
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support from the Wellcome Trust in the United Kingdom and
the involvement of groups in the United Kingdom, France,
Germany, and Japan.25 In its initial stages, the HGP sought to
build infrastructure, improve sequencing technologies, and
sequence the genomes of smaller model organisms. Building on
success with these early efforts, the international initiative to
sequence the human genome commenced in 1996 with plans to
complete the full sequence by 2005.26
By 1998, the HGP had spent nearly two billion dollars with
relatively little progress other than the sequences for the model
organisms.27 Then, in May, J. Craig Venter, a former NIH
scientist, famously proclaimed that he, funded by substantial
commercial backers, would utilize a battalion of three-hundred
state-of-the-art sequencing machines to sequence the entire
human genome in only three years, a full four years before the
publicly-funded HGP.28 Venter’s announcement led to a
technological “arms race” between his new company, Celera
Genomics, and the HGP, a race in which competing claims and
accusations became regular features in the scientific literature
and the popular press.29 Ultimately, a truce was declared, and,
in June 2000, the leaders of the competing groups made a joint
White House announcement that a “first draft” of the human
genome sequence had been completed.30 The draft sequence
was published in the public GenBank database in 2001.31

database at Los Alamos National Laboratory, which it established in 1983.
LARGE-SCALE SCIENCE, supra note 22, at 31. See generally Stephen
Hilgartner, Potential Effects of a Diminishing Public Domain in Biomedical
Research Data, in NATIONAL RESEARCH COUNCIL, THE ROLE OF SCIENTIFIC
AND TECHNICAL DATA AND INFORMATION IN THE PUBLIC DOMAIN:
PROCEEDINGS OF A SYMPOSIUM 137 (2003) (describing the history of GenBank
and its predecessor, the Los Alamos Sequence Library).
25. SHREEVE, supra note 9, at 45–47.
26. See NRC – GENOMIC AND PROTEOMIC RESEARCH, supra note 6, at 35.
27. Nicholas Wade, Scientist’s Plan: Map All DNA Within 3 Years, N.Y.
TIMES, May 10, 1998, at 20.
28. SHREEVE, supra note 9, at 22–23; Leslie Roberts, Controversial from
the Start, 291 SCIENCE 1182, 1187; Wade, supra note 27, at 1.
29. See Roberts, supra note 28, at 1188.
30. Roberts, supra note 28, at 1188; Nicholas Wade, Genetic Code of
Human Life is Cracked by Scientists: A Shared Success, N.Y. TIMES, June 27,
2000, at A1.
31. See HGP Initial Paper, supra note 4.
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4. The Post-Genome World
The completion of the human genome sequence has had a
significant impact on biomedical science.32 The genetic basis for
thousands of common hereditary diseases is now known, and
widely-available genetic tests exist for many common diseases
and other physical traits.33 Related fields such as proteomics
(the study of protein expression throughout an organism) have
also benefitted from the technological and scientific advances
made possible by the HGP.34 Today, additional international
efforts are under way to sequence the genomes of one thousand
individual humans to create the most complete and detailed
reference map of the human genome to-date (the “1000
Genomes Project”)35 and to sequence the genomes of some of
the multitude of microorganisms residing within the human
body (the “Human Microbiome Project”).36
The public human genome map has also enabled
researchers to conduct studies to determine complex
combinations of genetic factors contributing to disease.
Whereas earlier studies took years to identify single genes
responsible for specific inherited diseases, recent “genome-wide
association studies” (GWAS or GWA studies) have been
credited with identifying variants in multiple genes that
increase susceptibility for complex conditions such as Type 2
diabetes,37 breast cancer,38 prostate cancer,39 hypertension,40
32. See, e.g., COLLINS, supra note 1, at 3 (“[v]irtually all biomedical
researchers would agree that their approach to understanding how life works
has been profoundly and irreversibly affected by access to the complete DNA
sequence of the human genome, and that of many other organisms”).
33. As of December 6, 2009, NCBI’s GeneTests web site identified 1830
different diseases for which genetic tests are available. GENE TESTS,
http://www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests (last visited Dec.
6, 2009).
34. See NRC – GENOMIC AND PROTEOMIC RESEARCH, supra note 6, at 38–
40; LESK, supra note 1, at 305–07.
35. Erika Check Hayden, International Genome Project Launched, 451
NATURE 378, 378 (2008).
36. Peter J. Turnbaugh et al., The Human Microbiome Project, 449
NATURE 804, 804 (2007).
37. Laura J. Scott et al., A Genome-Wide Association Study of Type 2
Diabetes in Finns Detects Multiple Susceptibility Variants, 316 SCIENCE 1341
(2007); Robert Sladek, A Genome-Wide Association Study Identifies Novel Risk
Loci for Type 2 Diabetes, 445 NATURE 881(2007).
38. D.F. Easton et al., Genome-Wide Association Study Identifies Novel
Breast Cancer Susceptibility Loci, 447 NATURE 1087 (2007); D.J. Hunter et al.,
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and numerous other diseases.41 Such studies, which involve
scanning the entire human genome for variants that are
common among persons with similar diseases or other
observable traits, have been made possible by dramatic
advances in the technology used to sequence and analyze the
vast quantities of data embedded within human DNA and
similarly dramatic reductions in the cost of sequencing
technology.42
B. DATA AND DATABASES
1. Publication of Results
The peer-reviewed journal article is the traditional means
of disseminating scientific information.43 Scientists are judged,
both for purposes of career advancement and the awarding of
government grants, on the quantity of their publications,
A Genome-Wide Association Study Identifies Alleles in FGFR2 Associated with
Risk of Sporadic Postmenopausal Breast Cancer, 39 NATURE GENETICS 870
(2007).
39. Meredith Yeager et al., Genome-Wide Association Study of Prostate
Cancer Identifies a Second Risk Locus at 8q24, 39 NATURE GENETICS 645
(2007).
40. Adebowale Adeyemo et al., A Genome-Wide Association Study of
Hypertension and Blood Pressure in African Americans, PLOS GENETICS (July
2009), http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.
pgen.1000564.
41. See, e.g., The Wellcome Trust Case Control Consortium, Genome-Wide
Association Study of 14,000 Cases of Seven Common Diseases and 3,000
Shared Controls, 447 NATURE 661 (2007); Monya Baker, Genetics by Numbers,
451 NATURE 516 (2008) (discussing GWA study of several common diseases);
Lucia A. Hindorff et al., Potential Etiologic and Functional Implications of
Genome-Wide Association Loci for Human Diseases and Traits, 106
PROCEEDINGS OF THE NAT. ACAD. SCI. 9362 (2009) (discussing an online
catalog of GWAS association data that references hundreds of publications
identifying more than 100 diseases and traits).
42. In 1985, the cost of sequencing a single human DNA base pair was
approximately $10.00. That cost decreased to $1.00 by 1991, $0.10 by 1993,
and approximately $0.001 by 2006. LESK, supra note 1, at 23. Between 1999
and 2009, the cost of gene sequencing technology dropped by an astonishing
factor of 14,000. Collins, supra note 4, at 674. The NHGRI is currently
funding the development of technology capable of sequencing an entire human
genome (approximately 3.2 billion base pairs) for a cost of $1,000. See Collins,
supra note 4, at 675.
43. See ROBERT K. MERTON & HARRIET ZUCKERMAN, INSTITUTIONALIZED
PATTERNS OF EVALUATION IN SCIENCE (1971), reprinted in THE SOCIOLOGY OF
SCIENCE 460, 463–65 (Norman W. Storer ed., 1973) (tracing the origin of
scientific publication to the advent of printing and the establishment of the
first scientific journals in 1665).
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making the publication of articles of paramount importance to
many scientists and giving scientists a significant personal
incentive to publish and, thus, share their data with others.44
A significant period of time, however, typically elapses between
the point at which experimental data are generated and the
time that they are published. This delay reflects the time
required for the investigators to analyze their results, gather
additional data, refine their analysis, prepare a paper based on
their findings, and submit the paper to journals; for the
journals to conduct their peer review and editorial process; for
the investigators to make any revisions required by the
journals (including, at times, to conduct additional
experiments) or, if the paper is rejected by the journal, to revise
and submit it to different journals; and, finally, for the journal
to edit, format, and prepare the accepted paper for publication.
One recent study reports that the period from completion of
scientific work until publication is typically between twelve and
eighteen months.45 Older studies have found comparable or
longer delays in other fields of research.46

44. ROBERT K. MERTON, PRIORITIES IN SCIENTIFIC DISCOVERY (1957),
reprinted in THE SOCIOLOGY OF SCIENCE 286, 316 (Norman W. Store red.,
1979) (noting the “tendency, in many academic institutions, to transform the
sheer number of publications into a ritualized measure of scientific or
scholarly accomplishment”); RESEARCH INFO. NETWORK, TO SHARE OR NOT TO
SHARE: PUBLICATION AND QUALITY ASSURANCE OF RESEARCH DATA OUTPUTS
25 (2008), available at www.rin.ac.uk/data-publication (the assessment of
researchers is “perceived to value above all else the publication of papers in
high-impact journals”).
45. Carlos B. Amat, Editorial and Publication Delay of Papers Submitted
to 14 Selected Food Research Journals. Influence of Online Posting, 74
SCIENTOMETRICS 379 (2008).
46. See William D. Garvey & Belver C. Griffith, Scientific Information
Exchange in Psychology, 146 SCIENCE 1655, 1656 (1964) (reporting that in the
psychology field, their study indicated that the time between hypothesis and
publication is between 30 and 36 months, and the time between reportable
results and publication is between 18 and 21 months); Charles G. Roland &
Richard A. Kirkpatrick, Time Lapse Between Hypothesis and Publication in
the Medical Sciences, 292 NEW ENG. J. MED. 1273, 1274 (1975) (finding delays
of 20 and 24 months between the completion of research and publication,
respectively, for medical laboratory research and clinical research studies).
Anecdotally, the author has been informed that publication delays are
typically even longer in the social sciences.
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2. Raw Data
Despite the abundant incentives for scientists to share
data via publication, the data set published in most journal
articles represents only a small portion of the “raw” data
collected in a given research project.47 This data set is typically
presented in a summary fashion and is intended primarily to
support the scientist’s analysis and conclusions.48 Yet in order
to enable the verification and reproduction of an experiment by
other scientists, the full data set is often required. Thus, a
growing number of scientific journals now require that authors
make the data underlying their published results available to
readers as well.49 In the case of genomic sequence data,
journals often require a deposit of the data at the time of
publication into a public database,50 such as NIH’s Genbank51
or dbGaP52. These requirements, coupled with the funding
agency’s data release requirements described below, have
enabled the efficient, rapid, and cost-effective sharing of new
knowledge and the pursuit of studies and analyses that

47. See generally Rebecca S. Eisenberg, Patents and Data-Sharing in
Public Science, 15 INDUS. & CORP. CHANGE 1013, 1024 (2006).
48. Id.
49. See, e.g., Guide to Publication Policies of the Nature Journals,
NATURE, http://www.nature.com/authors/gta.pdf (last updated Apr. 30, 2009);
General Information for Authors, AM. ASS’N FOR THE ADVANCEMENT OF SCI.,
http://www.sciencemag.org/about/authors/prep/gen_info.dtl (last visited Oct.
27, 2010); Information for Authors, PROCEEDINGS OF THE NAT’L ACAD. OF SCI.,
http://www.pnas.org/site/misc/iforc.shtml#viii (last visited Oct. 27, 2010).
50. See Hilgartner, supra note 24, at 137.
51. Today, GenBank is administered by the National Center for
Biotechnology Information (NCBI) and forms one of three international
nucleotide libraries that work in close partnership, and the others are the
European Molecular Biology Library (EMBL) in Hinxton, England, and the
DNA Data Bank of Japan (DDBJ). See LESK, supra note 1, at 251. The
quantity of data in GenBank increased from about 2 billion base pairs in 1999
to 86 billion in 2008. Mike May, Sharing the Wealth of Data, SCI. AM.
WORLDVIEW 88, 89 (2009).
52. The Database of Genotypes and Phenotypes (dbGaP) operated by the
NIH’s National Library of Medicine can accommodate phenotypic data, which
includes elements such as de-identified subject age, ethnicity, weight,
demographics, exposure, disease state, and behavioral factors, which is far
more complex to record, search and correlate than the raw sequence data
deposited in GenBank, and in addition to genotypic and phenotypic data,
dbGaP can accommodate study documentation and statistical results,
including linkage and association analyses.
See generally DBGAP,
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=gap (last visited Oct. 27,
2010).
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otherwise might have been impossible.53 As Hess and Ostrom
observe, modern biology has been transformed into an
“information science.”54
C. ACTORS AND STAKEHOLDERS
Much of the early work regarding common resource
structures was devoted to understanding the attributes of the
different communities that shared the commons, whether
herdsmen grazing cattle on a common pasture or fishermen
trolling ocean stocks.55 This analysis is equally valuable in the
context of the information commons, and in designing “rules in
use,” policy makers must consider the interests of the different
communities that both use and develop the common resource,
including which interests may be overlapping, divergent, and,
sometimes, contradictory.56 The principal stakeholder
communities relevant to the genome commons, both initially
and as it has evolved over time, include the following:
1. Funders
The HGP, which cost over $2 billion to complete, has been
called “the largest and most visible large-scale science project
in biology to date.”57 As such, the U.S. governmental agencies
that funded the bulk of the massive project, together with their
counterparts at the Wellcome Trust in the United Kingdom,
exerted a significant degree of control over both its technical
and policy dimensions.58
Consistent with the perceived
importance of the project, NIH appointed “James Watson,
Nobel laureate and co-discoverer of the [double-]helical
structure of DNA,” to oversee the newly-formed National
53. See Eisenberg, supra note 47, at 1020.
54. Charlotte Hess & Elinor Ostrom, A Framework for Analysing the
Microbiological Commons, 58 INTL. SOC. SCI. J. 335, 335 (2006).
55. See, e.g., Cultural Commons, supra note 5.
56. Both Ostrom and Hess and Madison, Frischmann and Strandburg
emphasize the importance of identifying the various constituencies connected
with a cultural commons. Ostrom & Hess, supra note 19, at 48–50; Cultural
Commons, supra note 5, at 690. See also Contreras, Data Sharing, supra note
5, at 40–41.
57. LARGE-SCALE SCIENCE, supra note 22, at 29.
58. The Wellcome Trust in the U.K., at that time the world’s largest
private medical charity, also contributed substantial funding and support to
the project, primarily to the work conducted at the Sanger Centre in
Cambridge, England. LARGE-SCALE SCIENCE, supra note 22, at 39.
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Center for Human Genome Research in 1988.59
Other
scientists involved in the early planning and execution stages
of the project were also globally prominent and included a
significant number of Nobel Prize winners.60 This leadership
by preeminent and respected scientists was critical to the HGP
and gave the group’s decisions a gravitas that they otherwise
might have lacked. It also engendered among the project’s
leadership a sense of public stewardship that contributed to the
public-spirited nature of several HGP policies.61
2. Data Generators
Prior to the HGP, genetic research was conducted in
hundreds of academic laboratories across the world and funded
primarily by small grants directed toward the investigation of
specific hypotheses.62 The HGP, by contrast, treated the
mapping of the human genome as a campaign of large-scale
data production.63 The NIH funded three major genome centers
(Baylor College of Medicine, Washington University, and the
Whitehead Institute) that worked closely with the DOE’s Joint
Genome Institute and the Sanger Centre in Cambridge,
England (funded by the Wellcome Trust).64 These five centers
produced the majority of the data that resulted from the

59. Id. at 35. When Watson resigned in 1992 following a dispute over the
NIH’s attempts to patent small DNA fragments known as expressed sequence
tags (ESTs), Francis Collins, another high-profile scientist, was appointed to
replace him. Id. at 36–37.
60. In addition to Watson (Chemistry, 1962), the HGP leadership group
included Fred Sanger (Chemistry, 1958 and 1980), Hamilton Smith (Medicine,
1978) and Walter Gilbert (Chemistry, 1980). Other scientists involved in the
HGP won the Nobel Prize after the commencement of the project (e.g., John
Sulston (Medicine, 2002)). See generally Robert Mullan Cook-Deegan, Origins
of the Human Genome Project, 5 RISK 97 (1994).
61. For instance, in 1988, James Watson allocated 3% of the HGP budget
to investigate the ethical and social implications of sequencing the human
genome, creating the Ethical, Legal and Social Implications (ELSI) group
within the HGP, and the budget for ELSI was later raised to 5% of the HGP
budget, indicating the importance HGP leadership placed on the social impact
of the HGP. See James D. Watson, Genes and Politics, 75 J. MOLECULAR MED.
624, 633-34 (1997); Eric T. Juengst, Self-Critical Federal Science? The Ethics
Experiment Within the U.S. Human Genome Project, 13 SOC. PHIL. & POL’Y 63,
63 (1996); see also Peter Lee, Toward a Distributive Commons in Patent Law,
2009 WIS. L. REV. 917, 950-67 (2009) (analyzing the distributive justice
interests of public institutions which fund scientific research).
62. See Roberts, supra note 28, at 1185.
63. Id. at 1182.
64. See LARGE-SCALE SCIENCE, supra note 22, at 39.
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HGP.65 The intensity of this work, the amount of capital
equipment required to undertake it, and the degree of
specialization required by the new science of genomics led to
the creation of a new breed of scientist: one whose principal
research aim was the generation of large data sets rather than
the development and testing of hypotheses. This distinction
persists today as the number of data-generating projects in the
biosciences continues to increase.66 The factors motivating
these data-generating scientists are twofold: (1) obtaining
continued grant funding for their work and (2) advancing their
careers through publication and peer recognition. But while
governmental funding of new data generation projects
continues, data generating scientists face challenges when it
comes to publishing their work in traditional scientific
journals.67
3. Data Users
Prior to the completion of the HGP, researchers studying a
particular genetic disease devoted substantial time and effort
to isolating and sequencing the relevant gene—work that
would often take years of painstaking trial-and-error
experimentation.68 The data generated by the HGP and its
follow-up projects have eliminated the need for researchers to
conduct much of this groundwork.69 Unlike the close-knit
community of data generators at large-scale sequencing
centers, there is no coherent community of data users. These
users comprise all scientists across the world whose research
may benefit from the use of genomic data.

65. Id.
66. The implications of participating in large-scale data generating work
on the careers of junior scientists have been the subject of much discussion.
See LARGE-SCALE SCIENCE, supra note 22, at 26–27; Kaye et al., supra note
10, at 332–33; Toronto Int’l Data Release Workshop Authors, Pre-Publication
Data Sharing, 461 NATURE 168, 169–70 (2009) [hereinafter Toronto Report].
67. See Contreras, Prepublication Data Release, supra note 5, at 393;
Contreras, Data Sharing, supra note 5, at 38.
68. See SHREEVE, supra note 9, at 40.
69. Id.
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4. Data Intermediaries
Individual scientists and laboratories that generate data
are seldom the ones that make such data available to others,
except in limited one-on-one interactions with colleagues. In
most cases, scientists rely on data intermediaries, whether
scientific journals that publish their analyses and results or
centralized database managers that host large quantities of
raw data. Data intermediaries may operate either as
commercial entities (as in the case of commercial publishers
and paid database services) or non-profit/governmental entities
(such as the GenBank and dbGaP databases and “open access”
journals such as those published by the Public Library of
Science (PLoS)70). Not surprisingly, the interests of commercial
and non-commercial data intermediaries differ in several
regards, most notably in the area of pricing for access to
information. Nevertheless, these stakeholders also share a
number of common traits, including the desire to disseminate
information in ways that are effective, secure, and accurate and
the need to maintain some level of financial stability.71
5. Data Subjects
Human genomic information, by definition, is derived from
human subjects. Because the goal of the HGP was to generate a
baseline map of the human genome without regard to the
particular physiological and pathological traits associated with
genetic variation among individuals, the genomic sequence
data generated by the HGP was anonymous and retained no
association with the individual subjects whose DNA was
sequenced.72 Similar characteristics applied to other early

70. See Contreras, Data Sharing, supra note 5, at 38.
71. Subscription costs of scientific journals, particularly those of
commercial publishers, have risen sharply in recent years, and the scientific
publishing industry often complains of thinning margins and rising expenses,
issues not unique to the commercial sector while some publicly-funded
databases also suffer from funding shortfalls and are in danger of
discontinuation. See, e.g., Joan B. Schlimgen et al., Update on Inﬂation of
Journal Prices: Brandon/Hill List Journals and the Scientiﬁc, Technical, and
Medical Publishing Market, 92 J. MED. LIBR. ASS’N 307 (2004) (analyzing the
rising costs of scientific journals and the pressures causing that rise);
Editorial, Access Denied?, 462 NATURE 252 (2009) (describing the threatened
demise of the NSF-funded TAIR arabidopsis plant genome database).
72. The Human Genome Project Completion: Frequently Asked Questions,
NAT’L HUMAN GENOME RESEARCH INST., http://www.genome.gov/11006943
(last visited Oct. 28, 2010).
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genomic projects such as the HapMap Project.73 These data
were intended to elucidate non-individualized information
applicable to the human genome in general. In later projects,
however, and particularly with the commencement of largescale GWA studies, concerns with the potential identification of
human subjects grew because the genotypic data generated by
a GWA study is not meaningful without the associated
phenotypic data.74 That is, because a GWA study often seeks to
associate genotypic information (e.g., genetic markers) with
particular disease states, information regarding donor
demographics, disease state, and treatment are necessary to
interpret the genotypic findings. The prospect of releasing
clinical and phenotypic data to the public sparked substantial
concern and has led to the recognition of human data subjects
as important stakeholders in the genomic data equation.75
Public concern has only been heightened by the publication in
2008 of a paper suggesting that the presence of an identifiable
individual’s DNA can be inferred from a group of samples using
statistical techniques.76
Such findings suggest that the
interests of data subjects may require substantial attention as
genomic science advances and have led to numerous proposals
for heightened protection of individual identity in publiclyreleased genomic data.77

73. See Eisenberg, supra note 47, at 1026.
74. See Toronto Report, supra note 66, at 170.
75. For a general discussion of the protection of human subjects data in
genomic studies, a topic that is beyond the scope of this paper, but which has
been extensively addressed in the literature. See, e.g., LORI B. ANDREWS,
MAXWELL J. MEHLMAN & MARK A. ROTHSTEIN, GENETICS: ETHICS, LAW AND
POLICY 592–630 (1st ed. 2002); Domenic A. Crolla, Reflections on the Legal,
Social, and Ethical Implications of Pharmacogenomic Research, 46
JURIMETRICS 239, 241–47 (2006); John A. Robertson, Privacy Issues in Second
Stage Genomics, 40 JURIMETRICS 59 (1999).
76. Nils Homer et al., Resolving Individuals Contributing Trace Amounts
of DNA to Highly Complex Mixtures Using High-Density SNP Genotyping
Microarrays,
PLOS
GENETICS
(Aug.
2008),
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1
000167.
77. See, e.g., P3G Consortium et al., Public Access to Genome-Wide Data:
Five Views on Balancing Research with Privacy and Protection, PLOS
GENETICS
(Oct.
2009),
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1
000665.
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6. The Public
The general public cannot be ignored as a key stakeholder
with respect to genomic research. The HGP generated
significant public interest and was regularly covered by the
popular news media.78 Beyond general interest, however, are
two significant aspects of public engagement with genomics.
First, government-sponsored research is largely taxpayerfunded, meaning that public taxpayers and their
representatives in Congress have a legitimate and significant
interest in the direction and results of research.79 Second,
members of the public who are themselves affected, directly or
indirectly, by genetic disorders or diseases often form patient
advocacy and disease interest groups. These groups frequently
possess a high degree of familiarity with the relevant scientific
literature and have both the motivation and the financial
means to lobby for changes in research policy.80
III. THE EVOLUTION OF RAPID, PRE-PUBLICATION DATA
RELEASE IN THE GENOME SCIENCES
A. EARLY YEARS OF THE HGP
Since the initiation of the HGP, several factors contributed
to the call to release the data generated by the project to the
public. First, the early work of the HGP involved sequencing
the genomes of simple model organisms including the
roundworm (C. elegans) and mouse (Mus musculus). The
78. See, e.g., Nicholas Wade, Genome’s Riddle: Few Genes, Much
Complexity, N.Y. TIMES, Feb. 13, 2001, at F1, available at
http://www.nytimes.com/2001/02/13/health/13HUMA.html;
Justin
Gillis,
Scientists Speed Up Timetable for Mapping Human Genes, WASH. POST, Sept.
15, 1998, at A2; Leon Jaroff et al., Science: The Gene Hunt, TIME, Mar. 20,
1989,
at
62,
available
at
http://www.time.com/time/magazine/article/0,9171,957263,00.html.
79. See, e.g., Jonathan Karl et al., Stimulus Slammed: Republican
Senators Release Report Alleging Waste, ABC NEWS, August 3, 2010, available
at http://abcnews.go.com/GMA/stimulus-slammed-republican-senators-releasereport-alleging-waste/story?id=11309090 (detailing public and Congressional
criticism of research on topics such as cocaine use in monkeys, collection of
exotic ants and the use of yoga among cancer survivors).
80. See Lee, supra note 61, at 986–90 (addressing the interests and policy
concerns of disease advocacy groups); and see e.g., Sharon F. Terry et al.,
Advocacy Groups as Research Organizations: The PXE International Example,
8 NATURE REVIEWS GENETICS 157, 157–162 (2007) (describing the experience
of an advocacy organization for the disease pseudoxanthoma elasticum and
the methods the group used to advance a scientific agenda).
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groups that worked on these organisms abided by strong “open
science” norms and were accustomed to sharing their data
freely with one another, laying a strong precedent for the
HGP.81 Moreover, and perhaps more importantly, there was a
sense among the leadership of the project, in the words of Ari
Patrinos, the DOE’s Associate Director for Biological and
Environmental Research, that “the genome belongs to
everybody.”82 Accordingly, in 1988 the National Research
Council recommended that all data generated by the HGP “be
provided in an accessible form to the general research
community worldwide.”83
In 1992, shortly after the project was launched, NIH and
DOE developed formal guidelines for the sharing of HGP
data.84 These guidelines were viewed as essential to achieve the
program’s goals, avoid unnecessary duplication of effort, and
expedite research in other areas.85 In other words, the putative
purpose of these guidelines was to facilitate the
straightforward policy goal of project coordination. The
guidelines required that data generated by the HGP be
deposited in public databases (e.g., GenBank), making it
available to all scientists worldwide.86 But the need for project
coordination did not require immediate public release of the
81. See HGP Initial Paper, supra note 4, at 864; MCELHENY, supra note 1,
at xi (“Openness was at the core of the [bacteriophage] ethos, and it soon
propagated to the genetic research systems of the future.”); Hilgartner, supra
note 24, at 89 (“There were . . . communities doing molecular biology . . . on
yeast and Drosophila that had “open science” norms. Those norms were the
ones adopted as the models for the Human Genome Project.”). The evolution of
the open science culture among C. elegans researchers is described in some
detail in NRC - GENOMIC AND PROTEOMIC RESEARCH, supra note 6, at 54–56.
82. Eliot Marshall, Bermuda Rules: Community Spirit, With Teeth, 291
SCIENCE 1192 (2001). James Watson, then-director of the National Center for
Human Genome Research, wrote in 1990 that “making the sequences widely
available as rapidly as practical is the only way to ensure that their full value
will be realized and is the only acceptable way to handle information produced
at public expense.” Watson, supra note 1, at 48.
83. NAT’L RESEARCH COUNCIL, MAPPING AND SEQUENCING THE HUMAN
GENOME 8 (1988) [hereinafter NRC – HUMAN GENOME] (arguing that the
project’s mapping and sequencing data will be “of little value” if not made
accessible to the general research community).
84. NIH, DOE Guidelines Encourage Sharing of Data, Resources, HUMAN
GENOME NEWS (Oak Ridge Nat’l Laboratory, Oak Ridge, Ten.), Jan. 1993, at 4
[hereinafter NIH/DOE Guidelines].
85. Id.
86. Id.
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HGP data. The HGP policy makers in 1992 recognized the need
to provide data generators with “some scientific advantage from
the effort they have invested” in generating the data.87 This
“advantage” manifested itself in a six-month maximum period
from the time that HGP data are generated until the time that
they must be made publicly available. During this six-month
period, HGP researchers could analyze their data and prepare
publications. Only after the end of the six-month period were
they required to release the data to the public.88
The 1992 guidelines, in sharp contrast with later policies,
also indicate that the agencies would not disfavor investigators
that wished to secure patent rights in HGP-funded
discoveries.89 This patent-friendly attitude manifested itself in
NIH’s nearly disastrous attempt to seek patents on short
genetic sequences known as expressed sequence tags (ESTs).
This effort began in 1991, when NIH filed patent applications
claiming 337 ESTs identified, ironically, by Craig Venter’s
research group. NIH announced this filing as well as its
intention to continue to file EST patent applications on a
monthly basis.90 The public response to this announcement was
vociferous and triggered what Robert Cook-Deegan describes as
“an international firestorm.”91 The debate within NIH was
equally vehement and ultimately led to James Watson’s
resignation from the agency that oversaw the HGP.92 The EST
debacle marked a turning point in NIH’s attitude toward
patents on genetic material. By 1994, a significantly cowed
NIH elected not to appeal the Patent and Trademark Office’s

87. Id.
88. Id.
89. Id. (“[I]ntellectual property protection may be needed for some of the
data and materials.”).
90. See Thomas Barry, Revisiting Brenner: A Proposed Resolution to the
Debate Over the Patentability of Expressed Sequence Tags Using the Concept of
Utility Control, 35 AIPLA Q.J. 1, 11 (2007).
91. See COOK-DEEGAN, supra note 13, at 330–31 (detailing international
responses to NIH’s EST patent applications including UK threats to file
countervailing patent applications, UK and French efforts to forge an
international anti-patenting agreement, public commitments by Japanese
investigators not to pursue patents and pronouncements from various
international scientific conferences).
92. Watson decried the EST patenting plan as “sheer lunacy.” SHREEVE,
supra note 9, at 84–85. The NIH’s and DOE’s own advisory committees were
“unanimous in deploring the decision to seek such patents.” COOK-DEEGAN,
supra note 13, at 317.
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rejection of its initial EST patent applications,93 and, since
then, it has adopted a consistently lukewarm, if not outright
averse, attitude toward the patenting of genetic sequences.94
This attitude is reflected in NIH’s support for the Bermuda
Principles and in the data release and patent policies adopted
by NIH in the years thereafter.
B. THE BERMUDA PRINCIPLES
1. The Birth of Rapid Pre-Publication Data Release
The year 1996 marked a turning point for the HGP. Not
only was it the year in which sequencing of the human genome
was scheduled to begin, it also signaled a sea change in the
data release landscape. That February, approximately fifty
scientists and policy-makers met in Hamilton, Bermuda95 to
deliberate over the speed with which HGP data should be
released to the public and whether the six-month “holding
period” approved in 1992 should continue.96 The resulting
Bermuda Principles established that all DNA sequence
information from large-scale human genomic sequencing
93. See LARGE-SCALE SCIENCE, supra note 22, at 36–37. The patentability
of ESTs has subsequently been addressed by the U.S. Court of Appeals for the
Federal Circuit in In re Fisher, 421 F.3d 1365, 1374 (Fed. Cir. 2005) (holding
that the claimed ESTs do not meet the utility requirement of 35 U.S.C. § 101
because they do not identify the function for the underlying protein-encoding
genes).
94. In 1999, based partially on its experience with the EST patent
applications, NIH formally urged the PTO to impose stricter utility standards
when considering DNA-based patents. See NRC - GENOMIC AND PROTEOMIC
RESEARCH, supra note 6, at 53. For an overview of legal objections to the
practice of patenting ESTs, see id. at 52, and Barry, supra note 90, at 18–21.
95. The International Strategy Meeting on Human Genome Sequencing
meeting was sponsored by the Wellcome Trust and included representatives of
NIH and DOE, the Wellcome Trust, UK Medical Research Council, the
German Human Genome Programme, the European Commission, the Human
Genome Organisation (HUGO) and the Human Genome Projects of France
and Japan. In addition to the data release issues addressed in this paper, and
for which the meeting is best known, attendees also discussed and debated
issues relating to sequencing strategies, software tools and informatics
methodologies. See International Large-Scale Sequencing Meeting, HUMAN
GENOME NEWS (Oak Ridge Nat’l Laboratory, Oak Ridge, Ten.), Apr.–June
1996, at 19.
96. See Marshall, supra note 82, at 1192; Robert Cook-Deegan & Stephen
J. McCormack, A Brief Summary of Some Policies to Encourage Open Access to
DNA Sequence Data, 293 SCIENCE 217 supp. (2001), available at
http://www.sciencemag.org/cgi/content/full/293/5528/217/DC1.
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projects should be “freely available and in the public domain in
order to encourage research and development and to maximize
its benefit to society.”97 They went on to define the method by
which such data should be shared, requiring that sequence
assemblies greater than one kilobase (Kb) in length98 should be
released automatically within twenty-four hours and that
finished annotated sequences should be submitted immediately
to a public database.99
The Bermuda Principles were revolutionary in that they
established for the first time that data from public genomic
projects should be released to the public almost immediately
after their generation. Elimination of the six-month data
holding period established in 1992 was supported by both the
NIH and DOE and had significant international
ramifications.100 Even Craig Venter and Celera Genomics
eventually agreed to make the data from their competing effort
to sequence the human genome available to the public.101
97. Bermuda Principles, supra note 6.
98. Id. One kilobase (Kb) represents 1,000 base pairs. The human genome
consists of approximately 3.2 billion base pairs. One Kb is thus a very small
increment of the genetic code that corresponds to an initial “read” by gene
sequencing technology of the 1990s. At a follow-up meeting held in Bermuda
in 1997, this requirement was changed to apply to sequence assemblies of 2 Kb
or more in size to ensure that the released sequences include at least two
sequence reads for greater reliability.
99. Id.
100. Among other things, the Bermuda Principles contributed to the
German government’s 1997 decision to revoke its rule granting German
companies three months privileged access to human genome sequence data
generated with German government funding. Allison Abbott, Germany Rejects
Genome Data ‘Isolation’, 387 NATURE 536, 536 (1997).
101. Though Celera ultimately made its sequence data publicly-available,
the path that led to this result was bumpy and circuitous. Unlike the public
HGP, Celera offered its data on a commercial web site, rather than the public
GenBank database. Celera allowed scientists from non-profit and academic
institutions to access it without charge but required that scientists who
wished to use the data for commercial purposes enter into a license
agreement. Eliot Marshall, Storm Erupts over Terms for Publishing Celera’s
Sequence, 290 SCIENCE 2042, 2042 (2000). This approach outraged much of the
scientific community and led to a highly-publicized debate. Ultimately a
settlement was brokered by the journal Science, which published Celera’s
article announcing its draft of the human genome sequence, provided that the
company make its data broadly available (the competing HGP article was
published by Nature on the same day). Eliot Marshall, Sharing the Glory, Not
the Credit, 291 SCIENCE 1189–93 (2001). Celera’s subscription-based data
business was ultimately unsuccessful and, in 2005, the company finally
released its human, rat and mouse genomic data to GenBank. Jocelyn Kaiser,
Celera to End Subscriptions and Give Data to Public GenBank, 308 SCIENCE
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The Bermuda Principles achieved several of the most
important policy objectives held by the HGP funders. First,
they critically enhanced project coordination by enabling the
HGP sequencing centers to obtain regularly-updated data sets
from one another to avoid duplication of effort and to optimize
their respective tasks.102 Waiting six months to obtain data
under the 1992 policy was simply not practical if the project
were to function effectively. Second, the funders, particularly
the prominent leaders chosen to lead the HGP, argued that
rapid data release was the best way to maximize scientific
advancement (i.e., putting sequence data into the hands of as
many laboratories as possible as quickly as possible to
accelerate the solution of problems for the benefit of society).103
Finally, rapid data release under the Bermuda Principles
severely limited the ability of private parties to obtain patent
protection on data generated by the HGP, thus satisfying the
policy goal of minimizing encumbrances that was deeply held
by several HGP leaders.104 In particular, the Bermuda
Principles ensured that HGP data would be made publiclyavailable before data generators could file patent applications
covering “inventions” arising from that data and in a manner
that ensured its availability as prior art against third-party
patent filings at the earliest possible date.105 This result,
775, 775 (2005).
102. David R. Bentley, Genomic Sequence Information Should be Released
Immediately and Freely in the Public Domain, 274 SCIENCE 533, 533 (1996);
see also Adam Bostanci, Sequencing Human Genomes, in FROM MOLECULAR
GENETICS TO GENOMICS 174 (Jean-Paul Gaudilliére & Hans-Jörg Rheinberger
eds., 2004) (arguing that the immediate publication requirement was
successful in reducing the risk of duplication posed by researchers’ tendency to
focus on lucrative genes).
103. See Bentley, supra note 102, at 533 (insisting that, because sequences
derive their value from effective interpretation and use, the public good
requires that raw sequences be made available to the greatest number of
scientists as quickly as possible); Cook-Deegan & McCormack, supra note 96
(“[W]ithout [the Bermuda Principles], the wait for information sufficient to
meet patent criteria from high throughput sequencing programs would lead to
long delays, and thus be a serious drag on science, undermining the publicly
funded sequencing programs’ very purpose.”).
104. Bentley, supra note 102, at 533-34; see also Marshall, supra note 82;
JAMES D. WATSON ET AL., RECOMBINANT DNA 295 (3d ed. 2005).
105. In jurisdictions such as the European Union and Japan that have socalled “absolute novelty” requirements, an invention may not be patented if it
has been publicly disclosed prior to the filing of a patent application. See JOHN
GLADSTONE MILLS III ET AL., PATENT LAW FUNDAMENTALS §2:30 (perm. ed.,
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though praised by many, was also criticized by those who
believed that the NIH’s adoption of this anti-patenting
approach contravened the requirements of the Bayh-Dole Act of
1980, which expressly favors the patenting of federally-funded
inventions for the benefit of the U.S. economy.106
In response to this criticism, the National Human Genome
Research Institute’s (NHGRI) 1996 policy adopting the
Bermuda Principles explicitly acknowledges the Bayh-Dole Act,
noting that recipients of NIH funding have the right to choose
to apply for patents on inventions that “reveal convincing
evidence for utility,” but it goes on to warn that “NHGRI will
monitor grantee activity in this area to learn whether or not
attempts are being made to patent large blocks of primary
human genomic DNA sequence.”107 The consequences if such
rev. vol. May 2009). In such countries, a description of the invention in a
scientific journal could preclude the inventor from obtaining patent protection
for his or her invention. In the United States, a patent application may be filed
with respect to an invention that has been disclosed in a printed publication,
but only if the publication occurred less than one year before the filing of the
patent application. 35 U.S.C. § 102(b) (2006). Thus, if an inventor wishes to
seek patent protection for his or her invention, he or she must file a patent
application prior to the disclosure of the invention in a publication (or, in the
United States, no more than one year following publication). See Eisenberg,
supra note 47, at 1025–26 (discussing the creation of “patent-defeating” prior
art through the HGP’s data release rules).
106. Bayh-Dole Act of 1980, 35 U.S.C. §§ 200-12 (2006) (“It is the policy and
objective of the Congress to use the patent system to promote the utilization of
inventions arising from federally supported research or development.”). The
Act rationalized the previously chaotic rules governing federally-sponsored
inventions and allowed researchers to obtain patents on inventions arising
from government-funded research. Penalties, including forfeiture of rights,
could result from an institution’s failure to pursue patent protection for a
federally-funded invention. 35 U.S.C. § 202(c)(3). Commentators have argued
that NIH’s adoption of the rapid data release requirements of Bayh-Dole
deliberately thwart patent protection on genomic inventions. See Arti K. Rai &
Rebecca S. Eisenberg, Bayh-Dole Reform and the Progress of Biomedicine, 66
LAW & CONTEMP. PROBS. 289, 308 (2003) (“Arguably, NIH has acted outside
the scope of its statutory authority . . . at least with respect to patentable
inventions.”); SHREEVE, supra note 9, at 46 (“Strictly speaking, the policy
directly contradicted the Bayh-Dole Act.”).
107. NATIONAL HUMAN GENOME RESEARCH INSTITUTE, NHGRI POLICY
REGARDING INTELLECTUAL PROPERTY OF HUMAN GENOMIC SEQUENCE (April
9,
1996)
[hereinafter
NHGRI
1996
POLICY],
available
at
http://www.genome.gov/10000926. In a 1999 NIH-wide policy applicable to all
biomedical research tools, the agency expressly stated that the goals of the
Bayh-Dole Act can be met through publication or databank deposit of
generally-applicable research tools, and that restrictive licensing of such
inventions would be “antithetical” to the goals of the Act. Principles and
Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining
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patenting activity is discovered are left unstated, but the clear
implication is that the agency may view future grant
applications by “violators” unfavorably.108
The significance of NHGRI’s implementation of the
Bermuda Principles109 cannot be overstated. Prior to 1996,
NHGRI’s position with respect to data release and intellectual
property was not very different than that of other federal
agencies.110 But in the negotiations at and leading up to the
Bermuda meeting, the scientific community’s acknowledgement
of the collective norms of data sharing and the public domain,
bolstered by the gravitas of several Nobel laureates and other
leading figures, seems to have captured the agency’s
imagination. These norms have since become ingrained as part
of NHGRI’s basic position treating genomic data as a public
good that should be widely available and unencumbered.
2. Data Generators versus Data Users
In their effort to promote the policy goals of project
coordination, scientific advancement, and minimizing
encumbrances, the HGP organizers sacrificed the interests of
data generators. That is, the rapid data release requirements of
the Bermuda Principles effectively eliminated the ability of
and Disseminating Biomedical Research Resources: Final Notice, 64 Fed. Reg.
72,090, 72,093 (Dec. 23, 1999).
108. For a general critique of the NIH’s “hortatory” approach to this issue,
see Rai & Eisenberg, supra note 106, at 293-94, 306. Interestingly, the
National Cancer Institute (NCI) followed a different approach when
addressing concerns over the release of genomic data and the requirements of
the Bayh-Dole Act with its Cancer Genome Anatomy Program (CGAP) in
2000. Rather than issuing policy statements along the lines of NHGRI, NCI
invoked a seldom-used provision of the Bayh-Dole Act seeking a declaration of
“exceptional circumstances” to retain the intellectual property rights in cDNA
sequences generated by CGAP’s contractors. See NCI FREDERICK CANCER
RESEARCH AND DEVELOPMENT CENTER, MOLECULAR TARGET LIBRARIES
(MTLS), reprinted in COM. BUD. DAILY, Feb. 24, 2000. Because NCI did not
pursue patent protection for the sequences, they were effectively contributed
to the public domain. The procedures relating to such declarations of
“exceptional circumstances” are involved and time-consuming and, because
they have not been widely utilized, unpredictable. See Rai & Eisenberg, supra
note 106.
109. See NHGRI 1996 POLICY, supra note 107; NATIONAL HUMAN GENOME
RESEARCH INSTITUTE, CURRENT NHGRI POLICY FOR RELEASE AND DATABASE
DEPOSITION OF SEQUENCE DATA (Mar. 7, 1997) [hereinafter NHGRI 1997
POLICY], available at http://www.genome.gov/page.cfm?pageID=10000910.
110. See discussion of NASA and other federal policies supra note 8.
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data generators to publish analyses and conclusions based on
their data before others could access it via public means.111 The
implications of this effect were not realized immediately, but, in
the years immediately following the completion of the HGP, a
number of large-scale, publicly-funded genomics projects
adopted data release policies that reflect an increasing
recognition of the inherent tension between data generators
and data users. This distinction was first codified in a new
NHGRI data release policy adopted shortly after the Third
International Strategy Meeting on Human Genome Sequencing
held at Cold Spring Harbor in May 2000.112 The NHGRI 2000
policy reaffirmed the Institute’s 1997 Bermuda-based
requirement that initial genomic sequence assemblies be
deposited into GenBank within twenty-four hours of assembly
and extended the earlier policy to later-stage data. For the first
time, however, it also imposed formal requirements on users
who accessed and downloaded the released data. The policy
acknowledges “the widely accepted ethic in the scientific
community that those who generate the primary data freely
should have both the right and responsibility to publish the
work in a peer-reviewed journal.”113 Thus, the policy expressly
prohibits users from employing the public data “for the initial
publication of the complete genome sequence assembly or other
large-scale analyses,”114 thereby reserving this right to the data
generators. Moreover, when data users do utilize the publiclyavailable sequence data, they are required to acknowledge its
source.

111. Deanna M. Church & LeDeana W. Hillier, Back to Bermuda: How is
Science Best Served? 10 GENOME BIOLOGY 105, 105.1 (Apr. 24, 2009) (“[T]here
was some concern that [the policy] would jeopardize the genome center’s
ability to analyze and publish the data they had produced.”).
112. See NATIONAL HUMAN GENOME RESEARCH INSTITUTE, NHGRI POLICY
FOR RELEASE AND DATABASE DEPOSITION OF SEQUENCE DATA (Dec. 21, 2000)
[hereinafter
NHGRI
2000
POLICY],
available
at
www.genome.gov/page.cfm?pageID=10000910.
113. Id.
114. Id. While this prohibition represents an important gain for data
generators, it does not address their more fundamental concern with the
publication of analyses based on the data they have generated, as opposed to
the raw data itself.
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C. FT. LAUDERDALE AND COMMUNITY RESOURCE PROJECTS
(CRPS)
1. Reaffirmation of Bermuda
Questions regarding the ongoing validity of the Bermuda
Principles began to emerge following the completion of the
HGP. In order to address these concerns, the Wellcome Trust
sponsored a 2003 meeting in Ft. Lauderdale, Florida to revisit
rapid data release issues in the “post-genome” world. The
meeting was attended by representatives of funding agencies,
sequencing centers, database managers, biological laboratories,
and scientific journals, many of whom were involved in the
original
HGP.115
The
Ft.
Lauderdale
participants
“enthusiastically reaffirmed” the 1996 Bermuda Principles.116
The most significant outcome of the Ft. Lauderdale meeting
was a consensus that the Bermuda Principles should apply to
each “community resource project” (CRP), meaning “a research
project specifically devised and implemented to create a set of
data, reagents or other material whose primary utility will be
as a resource for the broad scientific community.”117
Under this definition, the twenty-four hour rapid release
rules of Bermuda would be applicable to large-scale projects
generating non-human sequence data (e.g., the Mouse Genome
Consortium), other basic genomic data maps (e.g., the SNP
Consortium and International HapMap Consortium), and other
collections of complex biological data, such as protein
structures and gene expression information.118 In order to
effectuate this data release requirement, funding agencies were
urged to designate appropriate efforts as CRPs and to require,
as a condition of funding, that rapid pre-publication data
release be required in such projects.119

115. Report of Meeting organized by the Wellcome Trust, Sharing Data
from Large-Scale Biological Research Projects: A System of Tripartite
Responsibility (Jan. 14–15, 2003), [hereinafter Ft. Lauderdale Principles],
available at http://www.genome.gov/Pages/Research/WellcomeReport0303.pdf.
116. Id. at 2 (recognizing, in addition, that considerations might apply to
data other than large-scale genomic sequences).
117. Id.
118. Id. at 2, 5.
119. Id. at 3.
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2. Different Data Types and Release Considerations
Notwithstanding this show of support, the Ft. Lauderdale
participants acknowledged that rapid pre-publication data
release might not be feasible or desirable in all situations,
particularly for projects other than CRPs. In particular, the
notion of a CRP, the primary goal of which is to generate a
particular data set for general scientific use, is often
distinguished from “hypothesis-driven” research in which the
investigators’ primary goal is to solve a particular scientific
question, such as the function of a specific gene or the cause of
a specific disease or condition.120 In hypothesis-driven research,
success is often measured by the degree to which a scientific
question is answered rather than the completion of a
quantifiable data set or other product. Thus, the early release
of data generated by such projects would generally be resisted
by the data generating scientists who carefully selected their
experiments to test as yet unpublished theories. Giving such
data away before their theories are finalized or published could
potentially enable a competing group to “scoop” the originating
group, a persistent fear among highly competitive scientists.
3. Adoption by NHGRI
As with the Bermuda Principles, the refinements agreed to
in Ft. Lauderdale were widely adopted, both by NHGRI and the
major sequencing laboratories. The NHGRI 2003 policy, issued
just a few weeks after the Ft. Lauderdale meeting, reiterates
the agency’s commitment to the Bermuda Principles “for all
types of large-scale DNA sequence data sets.”121 In the policy,
NHGRI recognizes the need for data generators to achieve
publications from the data they have released.122 Despite this
acknowledgement, the agency declines to impose any time
120. See, e.g., Kaye et al., supra note 10. An analogy to the distinction
between CRP and hypothesis-driven projects in biomedical science may be
drawn from geology. In geology, a CRP might be the U.S. Geological Survey’s
creation of a geophysical map of a region for the use of all interested
geologists, while a hypothesis-driven project might seek to determine whether
shale oil can be extracted from a particular valley in that region.
121. Reaffirmation and Extension of NHGRI Rapid Data Release Policies:
Large-Scale Sequencing and Other Community Resource Projects, NAT’L
HUMAN
GENOME
RESEARCH
INST.
(Feb.
2003),
http://www.genome.gov/10506537 [hereinafter NHGRI 2003 POLICY].
122. Id. (“[T]he sequence producers have a legitimate interest in publishing
peer-reviewed reports describing and analyzing the sequence they have
produced.”).
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limitation or other restriction on users of the released sequence
data. Instead, the policy strongly reaffirms NHGRI’s position
that DNA sequence data “should be available for all to use
without restriction” and urges data users to act in accordance
with “standard scientific norms” and to acknowledge data
generators in published analyses based on their data.123 These
recommendations, though indicative of NHGRI’s desired policy,
lack binding effect, which NHGRI acknowledges but fails to
remedy, stating that “even if the sequence data are occasionally
used in ways that violate normal standards of scientific
etiquette, unconditional release of sequence data from largescale sequence production centers is a necessary risk set
against the considerable benefits of immediate data release.”124
This statement provides little comfort to data generators who
are given no effective recourse if their data are used in a
manner that violates these standards.
4. The International HapMap Project, a New CRP
Beginning in 2002, a group of scientists and funding
agencies from Japan, the United Kingdom, Canada, China,
Nigeria, and the United States began a project to develop a
haplotype map of the human genome.125 The data release policy
of the HapMap Project is based on the Ft. Lauderdale
principles, and the project self-designates itself as a CRP.126
Data generated by the project “[were] released rapidly into”
publicly accessible databases,127 but access was subject to the
user’s consent to the terms of a standardized, online click-wrap
agreement.128
123. Id.
124. Id. (emphasis added).
125. See generally The Int’l HapMap Consortium, The International
HapMap Project, 426 NATURE 789, 790 (2003) (noting that a haplotype map
shows genomic “markers” that tend to recur in groups).
126. Id. at 793.
127. Id. SNP data were deposited in the NIH’s dbSNP database (a public
database), while genotype and haplotype data were made available through
the project’s data coordination center.
128. Id. A click-wrap agreement (alternatively referred to as a “clickthrough” or “click-to-accept” agreement or license) is “an electronic form
agreement to which [a] party may assent by clicking an icon or a button or by
typing in a set of specified words.” Christina L. Kunz et al., Click-Through
Agreements: Strategies for Avoiding Disputes on Validity of Assent, 57 BUS.
LAW. 401 (2001–2002). Rebecca Eisenberg, who analogizes the HapMap
Agreement to the open source software General Public License (GPL) raises
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The HapMap Project took several affirmative steps to
ensure that patents would not be filed by data generators, data
users claiming haplotypes, or other data generated by the
project.129 Most importantly, each user of HapMap data
(including data generators) was expressly prohibited from
restricting access to the HapMap database and, in particular,
from filing patent applications on the haplotypes or other
scientific data generated by the project.130 The HapMap
Consortium’s non-patenting requirement was viewed with
admiration by many, including policy makers at NHGRI.131
As a corollary to the provisions of its click-wrap agreement,
the HapMap Project adopted a “Data Release Policy,” setting
forth the participants’ somewhat conclusory position that raw
SNP and haplotype data lack “specific utility” necessary for
patent protection.132 The Policy also stated that, because the
Project will not relate genetic variants to medically relevant
conditions, “results that might be patentable can be obtained
only through additional studies not connected with the
HapMap Project.”133
5. The ENCODE Pilot Project
The Encyclopedia of DNA Elements (ENCODE) pilot
project was launched by NHGRI in 2003 as an effort to
elucidate the biological functions of various genetic elements.134
NHGRI issued a data release policy for the ENCODE pilot
questions about the enforceability of such agreements. Eisenberg, supra note
47, at 1028. For a general discussion of the enforceability of click-wrap
agreements, see generally GEORGE G. DELTA & JEFFREY H. MATSUURA, LAW OF
THE INTERNET § 10.05 (2d ed. 2008).
129. See The International HapMap Consortium, supra note 125, at 793.
130. Registration for Access to the HapMap Project Genotype Database,
INT’L HAPMAP PROJECT, http://hapmap.ncbi.nlm.nih.gov/cgi-perl/registration
(last visited Jan. 18, 2011) [hereinafter HapMap Agreement].
131. See ENCODE Project Data Release Policy (2003-2007), NAT’L HUMAN
GENOME RESEARCH INST., http://www.genome.gov/12513440 (last visited Oct.
18, 2010) [hereinafter ENCODE 2003 Pilot Policy]. (referring to the HapMap
Project’s successful policy of discouraging “parasitic patents”).
132. Data
Release
Policy,
INT’L
HAPMAP
PROJECT,
http://www.hapmap.org/datareleasepolicy.html (last visited Jan. 18, 2011).
133. Id. Though unclear from the HapMap project web site, Rebecca
Eisenberg reports that the Data Release Policy was adopted as late as 2004
and was intended to supersede the click-wrap structure. Eisenberg, supra note
47, at 1026.
134. The ENCODE Project Consortium, Identification and analysis of
functional elements in 1% of the human genome by the ENCODE pilot project,
447 NATURE 799 (2007).
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project closely following the Ft. Lauderdale principles.135 The
NHGRI designated the project as a CRP.136 As recommended in
Ft. Lauderdale, users of the data were urged to cite the data
generators in their analyses and to consider research
collaborations with them.137
With respect to intellectual property issues, the agency
first acknowledges the requirements of the Bayh-Dole Act by,
on one hand, stating that it has complied with those
requirements and, on the other, expressing its view that patent
protection for genomic sequence data is inappropriate.138 With
this preface, NHGRI acknowledges that the data created by the
ENCODE project will differ in character from the raw sequence
data generated by the HGP and HapMap project. That is, the
DNA sequence elements identified by ENCODE will, by
definition, “have biological function, and therefore might be
considered to have utility and be able to be patented.”139
Constrained by Bayh-Dole from expressly requiring researchers
to forego the opportunity to patent their federally-funded
inventions, NHGRI strongly “encourages all ENCODE data
producers to consider placing all information generated from
their project-related efforts in the public domain . . . .”140 In
addition, if grantees elect not to place their results in the public
domain, the agency encourages them to consider “maximal use
of non-exclusive licensing of patents to allow for broad access
and stimulate the development of multiple products.”141 This
language seems to represent NHGRI’s perception of the
greatest extent of its ability to promote the public domain over
patenting while remaining compliant with the letter of the
Bayh-Dole Act.

135.
136.
137.
138.
139.
140.
141.

See ENCODE 2003 Pilot Policy, supra note 131.
Id.
Id.
Id.
Id.
Id.
Id.
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D. EARLY PRIVATE SECTOR INITIATIVES
In addition to the HGP and other public sector sequencing
efforts described above, a number of private sector projects
made substantial contributions to the genome commons, many
with data release policies informed by the principles
established in Bermuda and Ft. Lauderdale.
1. The Merck Gene Index
As early as 1994, pharmaceutical manufacturer Merck,
collaborating with Lawrence Livermore National Laboratory
and Washington University, compiled the so-called “Merck
Gene Index,” a publicly accessible database of expressed
sequence tags (ESTs).142 By 1998, the Merck Gene Index had
released over 800,000 ESTs through GenBank.143 Merck’s
stated reason for contributing this potentially valuable data to
the public was the expansion of basic knowledge in the interest
of combating disease.144 While this goal is laudable, it was
generally acknowledged that another motivation for placing
these ESTs into the public was the pre-emption of patent filings
by biotech companies, several of which had already announced
business plans that involved the patenting and licensing of
ESTs and other genetic information.145
2. The SNP Consortium
An interesting and oft-cited parallel to the post-HGP
government-funded projects discussed above is that of the SNP
Consortium. This non-profit entity was formed in 1999 by a

142. See Press Release, Merck & Co., Inc., First Installment of Merck Gene
Index Data Released to Public Databases: Cooperative Effort Promises to
Speed Scientific Understanding of the Human Genome (Feb. 10, 1995),
[hereinafter
Merck
Gene
Index
Press
Release],
available
at
http://www.bio.net/bionet/mm/bionews/1995-February/001794.html; see also
supra notes 92–93and accompanying text (discussing ESTs and the patenting
debate surrounding them).
143. DON TAPSCOTT & ANTHONY D. WILLIAMS, WIKINOMICS: HOW MASS
COLLABORATION CHANGES EVERYTHING 166 (2006).
144. Merck Gene Index Press Release, supra note 142.
145. Marshall, supra note 82. Companies such as Incyte Pharmaceuticals
in Palo Alto, California, and Human Genome Sciences in Rockville, Maryland,
were then actively pursuing a business strategy of patenting, and licensing,
ESTs and other genetic data. Id.; See TAPSCOTT & WILLIAMS, supra note 143;
Arti Kaur Rai, Regulating Scientific Research: Intellectual Property Rights and
the Norms of Science, 94 NW. U. L. REV. 77, 134 (1999–2000).
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group of ten pharmaceutical companies146 and the Wellcome
Trust to identify and map genetic markers referred to as
“single nucleotide polymorphisms” (SNPs) and to release the
resulting data to the public domain.147 SNP data were publicly
released on the Consortium’s web site on a quarterly, and later
monthly, basis during the two-year research program, and also
deposited in GenBank.148 The Consortium ultimately mapped
1.4 million SNPs and created a genome-wide SNP-based
human linkage map, all of which were made publicly available
along with a number of query and search tools.149 Like the
Merck Gene Index, the SNP Consortium aimed to generate
data for the use of all researchers, unencumbered by patents.150
It accomplished this goal by filing U.S. patent applications
covering SNPs that it discovered and then contributing these

146. The SNP Consortium Ltd. was incorporated in March 1999 with the
following sponsoring (i.e., dues-paying) members: The Wellcome Trust
Limited, Pfizer Inc, Glaxo Wellcome Inc., Hoechst Marion Roussel, Zeneca
Inc., Hoffman-La Roche Inc., Novartis Pharmaceuticals Corporation, BristolMyers Squibb Company, SmithKline Beecham Corporation, Bayer Corporation
and Monsanto Corporation.
Technology giants Motorola, Inc. and
International Business Machines Corporation joined as sponsoring members
in November 1999 and Amersham Pharmacia Biotech Inc. became a
sponsoring member in 2001. Jorge Contreras, Personal Files (on file with
author).
147. SNPs are instances in which single base pairs in the genome differ
among individuals and occur roughly once per thousand base pairs. Though
the presence of certain SNPs has been associated with diseases, the purpose of
generating so-called SNP maps is to establish a uniform set of “mile markers”
along the vast genome. See Arthur Holden, The SNP Consortium: Summary
of a Private Consortium Effort to Develop an Applied Map of the Human
Genome, 32 BIOTECHNIQUES 22 (2002).
148. See Holden, supra note 147, at 25–26 and SNP Fact Sheet, U.S.
DEPARTMENT
OF
ENERGY
GENOME
PROGRAM,
http://www.ornl.gov/sci/techresources/Human_Genome/faq/snps.shtml#when
(last visited Jan. 18, 2011). The SNP Consortium’s data is currently hosted on
the International HapMap Project’s web site.
149. Holden, supra note 147, at 25–26. See also Gudmundur A. Thorisson
& Lincoln D. Stein, The SNP Consortium website: past, present and future, 31
NUCLEIC ACIDS RES. 124, 124–27 (2003) (providing a detailed description of
how the public can utilize the consortium’s website).
150. See, e.g., Holden, supra note 147, at 26 (“[t]he overall IP objective is to
maximize the number of SNPs that (i) enter the public domain at the earliest
possible date, and, (ii) are free of third-party encumbrances such that the map
can be used by all without financial or other IP obligations.”); TAPSCOTT &
WILLIAMS, supra note 143, at 168 (noting consortium members’ concerns about
biotech companies’ plans to patent SNPs and “sell them to the highest
bidder.”).
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applications to the public domain prior to issuance.151 This
approach ensured that the Consortium’s discoveries would act
as prior art defeating subsequent third-party patent
applications, with a priority date extending back to the initial
filings. The SNP Consortium’s innovative “protective”
patenting strategy has been cited as a model of the private
industry’s potential to contribute to the public genome
commons.152
E. SECOND GENERATION GENOMIC DATA RELEASE POLICIES
In the years following the Ft. Lauderdale meeting,
numerous large-scale genomic research projects have been
launched with increasingly sophisticated requirements
regarding data release. These policies implement their
requirements through contractual mechanisms that are more
tailored and comprehensive than the broad policy statements of
the HGP era. Moreover, increasingly sophisticated database
technologies have enabled the provision of differentiated levels
of data access, the screening of user applications for data
access, and improved tracking of data access and users.
1. Genetic Association Information Network (GAIN)
The Genetic Association Information Network (GAIN) was
established in 2006 by the Foundation for the National
Institutes of Health (FNIH), the NIH, and several
corporations.153 GAIN’s purpose was to conduct GWA studies of
151. The SNP Consortium’s patenting strategy included the filing of patent
applications covering all mapped SNPs and then converting those applications
into statutory invention registrations (SIRs) or abandoning the applications
after publication. See Identification and Mapping of Single Nucleotide
Polymorphisms in the Human Genome, U.S. Statutory Invention Registration,
No. H2220 (filed Aug. 8, 2001); Identification and Mapping of Single
Nucleotide Polymorphisms in the Human Genome, U.S. Statutory Invention
Registration, No. H2220 (filed Nov. 21, 2002).
152. See, e.g., Marshall, supra note 82, at 1192 (noting the consortium’s
“defensive move” deriving from the Merck Gene Index’s earlier strategy);
Cook-Deegan & McCormack, supra note 96 (describing the consortium’s
“unusual and sophisticated approach to keeping data in the public domain.”);
Allen C. Nunnally, Intellectual Property Perspectives in Pharmacogenomics, 46
JURIMETRICS 249, 252–53 (2006) (noting that the consortium members’
placement of the raw SNP map into the public domain did not necessarily
preclude their, or anybody else’s, patenting of subsequent discoveries made
using the basic research funded by the consortium).
153. See generally The GAIN Collaborative Research Group, New Models of
Collaboration in Genome-wide Association Studies: The Genetic Association
Information Network, 39 NATURE GENETICS 1045 (2007) (explaining the
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the genetic basis for six common diseases.154 Data generators in
the GAIN program were required to sign an applicant
agreement agreeing to various program commitments,
including “immediate” release of data generated by the
project.155 Over the course of the three-year project,
approximately 18,000 human DNA samples were genotyped.156
The resulting data was deposited in the Database of Genotypes
and Phenotypes (dbGaP) within the National Library of
Medicine at NIH.157
The dbGaP allows access to data on two levels: open and
controlled.158 Open access is available to the general public via
the Internet and includes non-sensitive summary data,
generally in aggregated form.159 Researchers wishing to access
data from the controlled portion of the database must register
with and be approved by the GAIN Data Access Committee
(DAC).160 They must also agree to keep the data secure, use it
only for approved research purposes, refrain from patenting the
data or conclusions drawn directly from the data, acknowledge
data generators, and refrain from attempting to identify
selection and characteristics of initial GAIN studies, the structure of GAIN,
and defining who has access to GAIN data).
154. The diseases studied were Attention Deficit Hyperactivity Disorder
(ADHD), diabetic nephropathy in Type 1 diabetes, major depression, psoriasis,
schizophrenia and bipolar disorder. Genetic Association Information Network
(GAIN),
FOUND.
FOR
THE
NAT’L
INST.
OF
HEALTH,
http://www.fnih.org/work/past-programs/genetic-association-informationnetwork-gain (last visited Oct. 28, 2010) [hereinafter FNIH Gain Information
Sheet].
155. The GAIN Collaborative Research Group, supra note 153, at 1048
(Box 1).
156. Teri A. Manolio, Collaborative genome-wide association studies of
diverse diseases: programs of the NHGRI’s office of population genomics, 10
PHARMACOGENOMICS 235, 236 (2009).
157. The combination of phenotypic data with genomic data is critical to
understanding disease and physiological traits having genetic influences. See
generally
DbGaP
Overview,
DBGAP-GENOTYPES
&
PHENOTYPES,
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/about.html (last visited Oct.
28, 2010). However, phenotypic data, which includes elements such as deidentified subject age, ethnicity, weight, demographics, exposure, disease state
and behavioral factors, are far more complex to record, search and correlate
than raw sequence data deposited in GenBank. Id. In addition to genotypic
and phenotypic data, dbGaP can accommodate study documentation and
statistical results, including linkage and association analyses. Id.
158. Id.
159. Id.
160. The Gain Collaborative Research Group, supra note 153, at 1049.
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individual study participants.161
Perhaps most importantly, the GAIN policy is the first
genomic data release policy to introduce a temporal restriction
on the users of the data (as opposed to the temporal release
requirements imposed on data generators by the Bermuda
Principles). That is, in order to secure a period of exclusive use
and publication priority for the data generators, data users are
prohibited from submitting abstracts and publications and from
making presentations based on GAIN data for a specified
embargo period.162 The duration of the embargo period for a
given data set is identified in the relevant data repository and
may vary by data set, but has generally been set at nine
months.163
2. The Cancer Genome Atlas (TCGA)
In 2006, the National Cancer Institute (NCI) and NHGRI
launched a pilot project to catalog genomic changes relating to
cancer.164 The Cancer Genome Atlas (TCGA) project generates
genomic sequence and related data, but also keeps track of
large amounts of clinical data, including patient diagnosis,
treatment history, and ongoing status.165 Due to the specialized
nature of the project data, deposits are made in both dbGaP
and a TCGA-specific database administered by NCI.166
Given the potential for identifying individual patients from
their genomic and phenotypic data, great attention was paid to
controlling access to TCGA data.167 Like GAIN data, TCGA
161. Data Use Certification Agreement, GENETIC ASS’N INFO. NETWORK
(GAIN)
(Dec.
3,
2008)
https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?view_pdf&stacc=phs000021.v1.p1
[hereinafter GAIN Data Use Agreement].
162. The GAIN Collaborative Research Group, supra note 153, at 1049.
163. Id.
164. See generally Francis S. Collins & Anna D. Barker, Mapping the
Cancer Genome, SCI. AM., Mar. 2007, at 50. The pilot project is scheduled to
conclude in October 2009. Id.
165. Types of Data, THE CANCER GENOME ATLAS DATA PORTAL,
http://cancergenome.nih.gov/dataportal/data/about/types/clinical/ (last visited
Oct. 28, 2010).
166. Data Use Certification Agreement, THE CANCER GENOME ATLAS PILOT
PROJECT
(Feb.
22,
2010)
http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&view_pdf&stacc=phs000
178.v1.p1.
167. A multi-constituency workshop was convened in May 2006 to discuss
proposed TCGA data access policies and practices. See generally Policies and
Guidelines,
THE
CANCER
GENOME
ATLAS,
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data is available in an open-access tier and a controlled-access
tier.168 Open-access is provided for data that cannot be
aggregated to generate an individually-identifiable dataset,
whereas controlled-access enables researchers to access clinical
and individually-unique data.169 Access to the controlled-access
data tier requires the user’s acknowledgement of a Data Access
Certification containing restrictions on research use, security,
transferability, and other matters that are nearly identical to
those in the GAIN agreement.170 One significant difference
from the GAIN agreement, however, is the absence in the
TCGA certification of a protected period for data generators.
Thus, while data users are requested to acknowledge the TCGA
in publications based on TCGA data,171 there is no embargo
restriction on the right of data users to submit abstracts or
publications derived from TCGA data.
3. The NIH GWAS Policy
In response to the growing number of GWA studies being
conducted and the large amount of genomic data generated by
such studies, in August 2007 the NIH released a new policy
regarding the generation, protection and sharing of data
generated by all federally-funded GWA studies.172 The NIH
GWAS Policy requires that grantees submit descriptive
information about each GWA study for inclusion in the “open

http://cancergenome.nih.gov/about/policies/informed_consent.asp (last visited
Oct. 28, 2010) (detailing the many considerations taken into account in
creating the policies for data access).
168. Data Access, THE CANCER GENOME ATLAS DATA PORTAL,
http://cancergenome.nih.gov/dataportal/data/access/ (last visited Oct. 28,
2010).
169. Id.
170. Compare Data Use Certification Agreement, supra note 166, with
GAIN Data Use Agreement, supra note 153.
171. TCGA Data Use Certification, supra note 166, at 7.
172. Policy for Sharing of Data Obtained in NIH Supported or Conducted
Genome-Wide Association Studies (GWAS), 72 Fed. Reg. 49290, 49294–97
(Aug. 28, 2007) [hereinafter NIH GWAS Policy]. Though the HGP and other
early genomic studies were conducted under the auspices of NHGRI, by 2006
most of the NIH Institutes were funding genomic research and GWA studies of
their own in support of their individual research missions. Modifications to
Genome-Wide Association Studies (GWAS) Data Access, NAT’L INST. OF
HEALTH
(Aug.
28,
2008)
http://grants.nih.gov/grants/gwas/data_sharing_policy_modifications_2008082
8.pdf [hereinafter Modifications to GWAS Data Access].
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access” portion of dbGaP.173 Grantees are also “strongly
encouraged” to submit study results, including phenotypic,
exposure and genotypic data, for inclusion in the “controlled
access” portion of the database “as soon as quality control
procedures have been completed.”174
Among the principal concerns raised concerning GWAS
data were those surrounding the public release of phenotypic or
clinical information that could eventually be traced back to
individual subjects.175 To address this concern, the NIH GWAS
Policy requires that GWAS data be de-identified in accordance
with HIPAA guidelines.176 Moreover, the data in the controlledaccess portion of the database may be released only after
approval of the proposed research use by a Data Access
Committee177 and then only under a signed Data Use
Certification that contains stringent protective clauses.178
Finally, the NIH sets forth its position that a request under the

173. Descriptive information includes the study protocol, questionnaires,
manuals, variables measured and other supporting documentation. NIH
GWAS Policy, supra note 172, at 49, 295. The NIH GWAS Policy was
amended in August, 2008, following the publication of a scientific paper
demonstrating that inferences regarding individual identity could be drawn by
analyzing allele frequency data in aggregated genomic data sets and other
statistical techniques. Modifications to GWAS Data Access, supra note 172.
Due to concerns relating to potential identification of GWAS subjects, NIH
withdrew certain GWAS-generated SNP data from the publicly-accessible
portions of dbGaP and certain NCI databases and placed them in the
controlled-access portions of these databases. Id.
174. NIH GWAS Policy, supra note 172, at 49295. As in the GAIN Policy,
access to the controlled-access portion of the database is regulated by a Data
Access Committee and carries stringent protective measures on the use of
data. Id. at 49296.
175. Id. at 49292 (summarizing public concerns over the availability of
personally-identifiable data). The NIH acknowledges that technologies either
in existence or likely to be available soon would make the identification of
individuals from raw genotypic and phenotypic data “feasible and increasingly
straightforward.” Id.
176. Id. at 49295 (citing the HIPAA Privacy Rule, 45 CFR 164.514(b)(2)).
177. The DAC is comprised primarily of NIH staff with expertise in the
relevant scientific disciplines, data privacy and data subject protection. Id. at
49296.
178. Like the certification required under the GAIN program, see supra
Section III.E.1, the GWAS Data Use Certification requires researchers and
their institutions to agree, among other things, to: use data only for the
approved research purpose, protect data confidentiality, implement
appropriate data security measures, not attempt to identify individual data
subjects, not sell any data, not share data with third parties, and to report
violations to the committee. NIH GWAS Policy, supra note 172, at 49296.
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Federal Freedom of Information Act (FOIA)179 for the release of
individually-identifiable GWAS information would constitute
an “invasion of personal privacy” under FOIA and will be
denied by NIH.180
The GWAS Policy addresses the publication priority
concerns of data generators by stating an expectation that
users of GWAS data refrain from submitting their analyses and
conclusions for publication, or otherwise presenting them
publicly, during an “exclusivity” period of up to twelve months
from the date that the data set is made available.181 The agency
also expresses a “hope” and expectation that “genotypephenotype associations identified through NIH-supported and
NIH-maintained GWAS datasets and their obvious
implications will remain available to all investigators,
unencumbered by intellectual property claims.”182 It goes on to
explain that “[t]he filing of patent applications and/or the
enforcement of resultant patents in a manner that might
restrict use of NIH-supported genotype-phenotype data could
diminish the potential public benefit they could provide.”183
However, in an effort to show some support for patent seekers,
the GWAS Policy also “encourages patenting of technology
suitable for subsequent private investment that may lead to
the development of products that address public needs.”184
4. International SAE Consortium
Since the successful completion of the SNP Consortium
project, several other privately-funded research collaborations
have adopted data release models that are similarly intended
to place large quantities of genomic data into the public
domain. One of these is the International Serious Adverse
179. See generally Federal Freedom of Information Act, 5 U.S.C. § 552
(2006).
180. NIH GWAS Policy, supra note 172, at 49292 (citing FOIA Exemption
6, 5 U.S.C. §552(b)(6)).
181. This exclusivity period was originally nine months when the GWAS
Policy was released for public comment, but was subsequently lengthened to
twelve months. Request for Information (RFI): Proposed Policy for Sharing
of Data obtained in NIH supported or conducted Genome-Wide Association
Studies
(GWAS),
NAT’L INST. OF HEALTH
(Aug.
30,
2006)
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-094.html.
182. NIH GWAS Policy, supra note 172, at 49296.
183. Id. at 49297
184. Id. at 49296.
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Event Consortium (iSAEC), a group of pharmaceutical
companies formed in 2007 to fund research toward the
identification of DNA markers for drug-induced serious adverse
events.185 The Consortium works with academic collaborators
to collect DNA samples and associated phenotypic data and to
then conduct GWA studies, targeted sequencing, and statistical
analyses to identify potential markers and associations of
interest.186 Since its formation, iSAEC studies have identified
DNA markers relating to drug-induced liver injury (DILI)187
and serious skin rash (SSR). The iSAEC seeks to minimize
patent encumbrances on genetic markers and associations that
it identifies via a “protective” patent strategy modeled on that
of the SNP Consortium. To date, patent applications claiming
various DNA markers relevant to DILI and SSR have been
filed with the intention that they will be abandoned following
publication.188 Like the GAIN and other policies discussed in
this section, the iSAEC imposes various security, research
purpose, and non-patenting restrictions on data that is publicly
released. It also secures for data-generating scientists a period
of exclusivity (up to twelve months) during which they have
sole access to the data.189 During this time, they have the
ability to analyze data and prepare papers for publication
without the threat of being scooped by competing groups. While
the research funded by iSAEC would not typically be
considered a “community resource project” as defined in Ft.
Lauderdale (as its goal is not the creation of a large, generallyapplicable data set),190 the Consortium has still committed to
release its data to the public, albeit on a delayed basis. This
approach illustrates an effective compromise among the
interests of data generators in a hypothesis-driven research

185. iSAEC’s Background and Organizational Structure, INT’L SAE
CONSORTIUM, http://www.saeconsortium.org/ (last accessed Oct. 28, 2010).
186. Id.
187. See generally Ann K. Daly et al., HLA-B*5701 Genotype is a Major
Determinant of Drug-Induced Liver Injury due to Flucloxacillin, 41 NATURE
GENETICS 816 (July 2009) (discussing the genetic basis for susceptibility to
drug-induced liver injury from flucloxacillin).
188. Biomarkers for Drug-Induced Liver Injury, U.S. Patent App.
12/505,058 (filed Jul. 17, 2009); Biomarkers for Serious Skin Rash, U.S.
Patent App. 61/112,983 (filed Nov.10, 2009); Biomarkers for Serious Skin
Rash, U.S. Patent App. 61/168,875 (filed Nov. 10, 2009).
189. Int’l SAE Consortium Ltd., DATA RELEASE AND INTELLECTUAL
PROPERTY POLICY (last amended Nov. 5, 2009) (on file with author).
190. See supra Section III.C.1.
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model and the community of data users and funders.191
5. The Full ENCODE Project and modENCODE
In 2007 NHGRI expanded the ENCODE pilot project192 to
cover the entire human genome and launched a corollary
project (modENCODE) to identify the functional genomic
elements of two common model organisms, the roundworm (C.
elegans) and fruit fly (Drosophila melanogaster).193 This
expansion involved an overhaul of the 2003 ENCODE data
release policy and resulted in a new policy in 2008 covering
both the expanded ENCODE project and modENCODE.194 The
ENCODE 2008 Policy has much in common with its 2003
predecessor, though it also introduces some of the policy
features added by the later GAIN and GWAS policies. Thus,
while the ENCODE 2008 Policy continues to use the Ft.
Lauderdale terminology in designating itself a “community
resource project,” it also recommends a nine month embargo
period during which users of released data are requested not to
publish or present results based on that data.195
The ENCODE 2008 Policy is among the most complex data
release policies to date, as it distinguishes between published
and unpublished data, verified and unverified data, and offers
several examples of the data use implications for different
types of studies conducted with ENCODE data.196 The length
and complexity of the policy evidences the desire of the agency
and the participants for clear guidelines and avoidance of
misunderstandings regarding the release of data, as the
diversity of participants, organisms, and data types has
expanded dramatically beyond those originally considered by
the framers of the Bermuda Principles.

191. The compromises and negotiation strategy inherent in this approach
is discussed in greater detail in Contreras, Data Sharing, supra note 5, at 11.
192. See supra Section III.C.5.
193. See Susan E. Celniker et al., Unlocking the Secrets of the Genome, 459
NATURE 927 (2009) (describing the modENCODE project methodology and
goals).
194. ENCODE Consortia Data Release, Data Use, and Publication Policies
(2008),
NAT’L
HUMAN
GENOME
RESEARCH
INST.,
http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolic
yFinal2008.pdf [hereinafter ENCODE 2008 Policy].
195. Id. at 4.
196. Id. at 5–7.
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F. POLICIES OUTSIDE THE UNITED STATES
Although the HGP and subsequent genome sequencing
projects relied on international cooperation and collaboration,
the data release policies adopted by groups outside the United
States have differed in material ways from corresponding
policies adopted by NIH and NHGRI. In particular, non-U.S.
funding agencies have generally exhibited less concern with
patenting issues and have remained more flexible with respect
to the timeframes for both release of data by data generators
and embargo periods on publication for data users.197 A few
examples of recent non-U.S. data release policies are described
below.
1. Genome Canada
Genome Canada, a participant in the HGP, adopted its
first formal data release policy in 2005.198 While acknowledging
the Ft. Lauderdale principles, the Canadian policy does not
adopt the 24-hour release requirement set forth in the earlier
Bermuda Principles. With respect to data generators, Genome
Canada “expects data to be released and shared no later than
the original publication date” of the researchers’ results,
provided that all data must be released “without restriction” by
the end of a project.199 For patents, Genome Canada “recognizes
the need to protect patentable and other proprietary data” and,
thus, requires that the data generators’ obligation to release
data occur upon the publication or the filing of a patent
application, whichever is earlier.200
2. Wellcome Trust Case Control Consortium (WTCCC)
The Wellcome Trust is the largest charity in the United
Kingdom and the second-largest biomedical research funding
charity in the world. Since the beginning of the HGP, the
197. The reason for this divergence is not clear, though it is possible that
the absence of an equivalent to the Bayh-Dole Act in most countries, as well as
a patenting landscape that is generally more restrictive outside the U.S., has
made patent and data release issues less central to policy discussions outside
the U.S.
198. Genome Canada, DATA RELEASE AND RESOURCE SHARING (Sept. 18,
2008),
available
at
http://www.genomecanada.ca/medias/PDF/EN/DataReleaseandResourceShari
ngPolicy.pdf.
199. Id.
200. Id. (also allowing for extensions of up to 90 days in the event of
“extenuating circumstances”).
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Wellcome Trust has supported genomics initiatives both
through direct funding and through its Sanger Institute in
Cambridge, England, a leading sequencing center.201 In 2006,
the Trust funded a large-scale GWA study of seven complex
human diseases that was conducted by more than fifty research
groups from institutions across the United Kingdom.202 The
study generated a large quantity of data, including aggregated
and individual-level genotypic and phenotypic information.
Most of this data was made available to the public in
accordance with the Ft. Lauderdale Principles, and the project
self-designated itself as a CRP.203
In order to ensure appropriate use of released data, the
WTCCC requires all prospective data users to apply to the
Consortium’s Data Access Committee and sign a written Data
Access Agreement.204 Access to data is granted only to qualified
investigators for “appropriate use,” as determined by the
committee.205 The data access agreement requires security,
acknowledgement, transfer, and use restrictions comparable to
those found in the GAIN and other recent policies.206 It also
includes some restrictions that are specific to the study
samples, such as a prohibition on any use of data from the 1958
British Birth Cohort for commercial purposes.207 The
agreement does not, however, contain any specific embargo on
publication or any restriction on patenting activity.

201. See
generally
WELLCOME
TRUST,
http://www.wellcome.ac.uk/index.htm (last visited Oct. 26, 2010).
202. The main study covered 2,000 cases and 3,000 shared controls drawn
primarily from British subjects for the following seven conditions: bipolar
disorder, coronary artery disease, Chron’s disease, hypertension, rheumatoid
arthritis, type 1 diabetes and type 2 diabetes. The Wellcome Trust Case
Control Consortium, supra note 41.
203. Publications Policy, WELLCOME TRUST CASE CONTROL CONSORTIUM,
https://www.wtccc.org.uk/ccc1/publications_policy_ext.shtml (last visited Oct.
26, 2010).
204. See WTCCC: Access to Genotype Data, WELLCOME TRUST CASE
CONTROL
CONSORTIUM,
https://www.wtccc.org.uk/docs/CDAC_Guidelines_and_Information_July09.pdf
(last visited Oct. 26, 2010); Data Access Agreement, THE WELLCOME TRUST
CASE
CONTROL
CONSORTIUM,
https://www.wtccc.org.uk/docs/Data_Access_Agreement_v15.pdf (last visited
Oct. 26, 2010).
205. WTCCC: Access to Genotype Data, supra note 204, at §4.
206. Data Access Agreement, supra note 204.
207. Id. at §2.
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3. UK Medical Research Council
In 2008 the United Kingdom’s Medical Research Council
(MRC) released a comprehensive set of guidelines surrounding
release of data from MRC-funded research.208 In a set of broad
“data access principles,” the MRC announces that data
generated by publicly-funded research are a public good and, as
such, “must be made available for new research purposes in a
timely, responsible manner.”209 Following the reasoning behind
the Ft. Lauderdale principles, the MRC states that access to
data “must balance the interests of data creators, custodians,
users and data subjects,”210 and acknowledges that “limited,
defined” periods of exclusive use “will often be justifiable.”211
Beyond these broad pronouncements, however, the MRC gives
little specific guidance with respect to the timing or manner of
data release.
Like the WTCCC guidelines, the MRC guidelines place a
high value on formal, written agreements to govern the
relationships between data generators and data users. Such
agreements “must” be used if restrictions on the use of data are
to be imposed and are “particularly important” when
publication rights and intellectual property are implicated.212
The MRC, however, by and large allows individual parties to
define the specific requirements of their data sharing
agreements and does not attempt to impose over-arching rules
regarding the timing of data release.

208. Principles for Access to, and Use of, MRC Funded Research Data,
MEDICAL
RESEARCH
COUNCIL
http://www.mrc.ac.uk/consumption/groups/public/documents/content/mrc00375
9.pdf (last visited Oct. 26, 2010) (Because the MRC broadly addresses
biomedical research across many fields, the MRC guidelines do not focus on
genomic data, nor do they expressly reference the Bermuda or Ft. Lauderdale
principles, despite MRC’s participation in the original Bermuda meeting).
209. Id. at 1.
210. Id.
211. Id. at 4.
212. Id. at 5 para. 8.
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G. RECENT DEVELOPMENTS IN RAPID PRE-PUBLICATION DATA
RELEASE
1. Amsterdam: Proteomics Joins the Fray
The success and broad adoption of genomics data release
policies incorporating the Bermuda and Ft. Lauderdale
Principles have recently led scientists in related fields to
consider the adoption of analogous principles in their own
research. One prominent example occurred in 2008, when the
NCI convened a meeting of proteomics213 researchers in
Amsterdam to “identify and address potential roadblocks to
rapid and open access to [proteomics] data.”214
Participants identified technical, infrastructure, and policy
challenges to the rapid release of proteomic data. Technical
challenges included the wide variety of disparate platforms and
techniques used to generate proteomic data, making “raw” data
from experimental instruments difficult to interpret by
scientists unfamiliar with or lacking access to the instruments
used to generate the data.215 Proteomics also lacks the
established public database infrastructure of genomics.
Whereas DNA sequence data can be deposited readily in
GenBank, the EMBL, or DDBJ and is often deposited in all
three, there is no common public data repository for proteomic
data, and existing proteomic databases suffer from inconsistent
and sometimes incompatible data formats.216 Finally, unlike
genomics, in which the entire field focused for several years on
the single HGP project, proteomics research lacks a unifying
policy core, and proteomics-focused journals have each
developed their own, sometimes inconsistent, guidelines for

213. Proteomics is the study of protein structures. Unlike DNA sequences,
which are linear arrangements of the four basic nucleotides, A, C, T and G,
proteins consist of intricately-folded, three-dimensional structures formed
from twenty different amino acids. Unlike today’s relatively straightforward
and automated DNA sequencing technologies, the techniques for elucidating
protein structures include electrophoresis, various forms of mass spectrometry
and an increasing number of other methods. See generally LESK, supra note 1,
at 312–22.
214. Henry Rodriguez et al., Recommendations From the 2008
International Summit on Proteomics Data Release and Sharing Policy: A
Summit Report, 8 J. PROTEOMICS RES. 3689 (2009).
215. See id. at 3689–90.
216. Id. at 3690.
Existing proteomic databases include GPMDB,
UniProtKB, Peptide Atlas, PRIDE and NCBI’s Peptidome. Id.

121_CONTRERAS.DOCX (DO NOT DELETE)

2011]

BERMUDA’S LEGACY

4/4/2011 8:14 AM

109

data submission.217
Notwithstanding these difficulties, the Amsterdam
participants articulated six data release and sharing principles
that reflect the spirit of the Bermuda and Ft. Lauderdale
Principles, but which lack the specificity of the genomics
policies. The six Amsterdam principles are: (1) Timing (should
depend on the nature of the effort generating the data, but in
no event should be later than publication or, for community
resource projects, following appropriate quality assurance
procedures), (2) Comprehensiveness (full raw data sets should
be released together with associated metadata and quality
data), (3) Format (standardized formats are encouraged), (4)
Deposition to repositories (central repositories for proteomic
data should be established), (5) Quality metrics (central
repositories should develop metrics for assessing data quality),
and (6) Responsibility (scientists, funding agencies, and
journals share responsibility for ensuring adherence to
community data release standards).218
2. The Toronto Data Release Workshop
In 2009, more than a hundred scientists, journal editors,
legal scholars, and representatives of governmental and private
funding agencies met in Toronto to assess the current state of
rapid pre-publication data release and the applicability of the
Bermuda Principles in projects well beyond the generation of
genomic sequence data.219 The participants reaffirmed a
general community commitment to rapid pre-publication data
release, expanding the scope of projects as to which of these
principles should apply to all biomedical datasets having
“broad utility, are large in scale . . . and are ‘reference’ in
character.”220 Specifically, in addition to genomic and proteomic
studies, they cited structural chemistry, metabolomics, and
RNAi datasets, as well as annotated clinical resources such as
cohorts, tissue banks, and case-control studies.221
The expansion of rapid pre-publication data release
principles beyond genomics and proteomics projects, which
often have as their ultimate goal the generation of a large data
217. Id.
218. Id. at 3690–91.
219. See Toronto Report, supra note 66.
220. Id. at 168. To some degree, this characterization is a restatement of
the Ft. Lauderdale definition of “community resource projects”.
221. Id.
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set, to these other areas necessarily raises issues concerning
the appropriateness of rapid data release in hypothesis-driven
research. Accordingly, the Toronto participants concurred that,
while funding agencies should require rapid pre-publication
data release for “broad utility” projects, rapid data release
“should not be mandated” for projects that are generally
hypothesis-driven.222 The Toronto participants also addressed
the priority concerns of data generators versus data users,
observing anecdotally that data users have in many cases
published papers based on publicly-released data sets before
the publication of the data generators’ papers analyzing the
data sets themselves, and that this situation caused no “serious
damage” to the data generators’ subsequent publications.223
Nevertheless, the participants acknowledged the acceptability
of a “protected period” during which data users could be
restricted from publishing on released data sets, cautioning,
however, that this period should never exceed one year.224 The
Toronto participants produced a set of “best practices”
embodying these principles and applying them to the three
constituencies originally identified in Ft. Lauderdale—funding
agencies, data generators and data users—as well as to the
scientific journals, which were urged to monitor and provide
guidance relating to data release issues.225
Discussions in Toronto also addressed issues of intellectual
property. In particular, it was observed that, as data sets
subject to rapid pre-publication release expand beyond genomic
and proteomic “basic science” and begin to embody greater
functional content and clinical utility, the patentability of this
information will be less open to debate, and the early release of
such information will have a greater impact on the data
generators’ ability to secure patent protection with concomitant
implications for U.S. funding agencies subject to Bayh-Dole
requirements.226 Given the controversial nature of this subject
and the lack of consensus on this issue, the subject of
intellectual property was ultimately excluded from the
published meeting report. It is inevitable, however, that
222. Id. at 169.
223. Id. at 169–70.
224. Id. at 170.
225. Id.
226. Author’s personal notes, The Toronto Data Release Workshop (May
13-14, 2009) (on file with author).
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intellectual property issues will play an increasingly important
role in discussions of rapid pre-publication data release in fields
of medical significance.
3. New Policies and Projects
The influence of the Bermuda/Ft. Lauderdale Principles
has been lasting and pervasive. The list of new biomedical
research projects that are currently developing or have recently
adopted data release policies based on these principles or their
progeny is too long to list here, but includes projects such as the
1000 Genomes Project,227 the International Cancer Genome
Consortium,228 and the Human Microbiome Project.229 NIH and
NHGRI are in the process of considering further revisions to
their institutional data release policies and collecting feedback
from various stakeholder groups.230 Though the result of this
latest round of revisions have not yet been released, it is likely
that any new NIH data release policy will continue to refine the
rules of rapid pre-publication data release to take into account
the policy considerations and objectives described above.
IV. POLICY CONSIDERATIONS IN GENOMIC DATA
RELEASE POLICIES
A. ELEMENTS OF POLICY DESIGN
The preceding Section describes the major genomicsrelated data release milestones and policies from the beginning
of the HGP through today, a span of nearly two decades. Table
1 below summarizes the manner in which each of these policies
handles issues relating to the speed of data release, restrictions
on data use, and intellectual property.

227. See 1000 Genomes Data and Sample Information, 1000 GENOMES,
http://www.1000genomes.org/page.php?page=data (last visited Oct. 28, 2010).
228. See INTERNATIONAL CANCER GENOME CONSORTIUM, GOALS,
STRUCTURES, POLICIES & GUIDELINES 15 (2008), available at
http://www.icgc.org/files/icgc/ICGC_April_29_2008_en.pdf.
229. See HMP Data Release and Resource Sharing Guidelines for Human
Microbiome Project Data Production Grants, NIH COMMON FUND,
http://commonfund.nih.gov/hmp/datareleaseguidelines.asp (last visited Oct.
28, 2010).
230. National Institutes of Health, Notice on Development of Data Sharing
Policy for Sequence and Related Genomic Data (Oct. 19, 2009), available at
http://grants1.nih.gov/grants/guide/notice-files/NOT-HG-10-006.html.
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Table 1: Comparative Summary of Genomics Data
Release Policies

NIH-DOE
1992
Guidelines

Bermuda
Principles
(1996)
NHGRI
1996 Policy

Type of
Data

Release
Speed

User
Restrictio
ns
None233

Materials
and data
produced
by the
HGP231

Within 6
months
after
generation

Initial
genome
sequence
reads >
1Kb235
Human
genomic
DNA
sequence
data
produced
under the
HGP239

24 hours
after
generation

None237

As rapidly
as
possible240

None241

232

Patent
Considerat
ions
IP
protection
“may be
needed” for
some data
and
materials234
Not
specified238

236

“raw human
genomic
DNA
sequence . . .
is an
inappropriat
e material
for patent
filing”242

231. NIH/DOE Guidelines, supra note 84.
232. Id.
233. Id.
234. Id.
235. Bermuda Principles, supra note 6. Initial genome sequence reads were
increased to 2 Kb under the Bermuda 1997 Report. Id..
236. Contreras, Prepublication Data Release, supra note 5, at 393.
237. Id.
238. See id.
239. NHGRI 1996 POLICY, supra note 107.
240. Id.
241. Id.
242. Id.
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NHGRI
1997 Policy

SNP
Consortiu
m (1998)247

NHGRI
2000 Policy

Type of
Data

Release
Speed

Large-scale
genomic
DNA
sequence
data243
SNP map
and
association
data248

24 hours
after
generation

Sequence
trace data
and
ancillary
information
252

User
Restrictio
ns
None245

Patent
Considerat
ions
Not
specified246

Monthly/q
uarterly
releases to
web site249

None250

Deposited
weekly
into the
NCBI
Trace
Repository

Users may
not use
data for the
initial
publication
of the
complete
genome
sequence
assembly
or other
large-scale
analyses254

protective
filing
strategy to
release data
to public
domain251
Not
specified255

244

253

243.
244.
245.
246.
247.
248.
249.
250.
251.
252.
253.
254.
255.

113

NHGRI 1997 POLICY, supra note 107.
Id.
Id.
See id.
Holden, supra note 147 at 22–26.
Id.
Id. at 26.
See id. at 22–23.
Id. at 26.
NHGRI 2000 Policy, supra note 112.
Id.
Id.
See id.
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Type of
Data

Release
Speed

Ft.
Lauderdale
Principles
(2003)

All data
from
Community
Resource
Projects256

NHGRI
2003 Policy

Large-scale
sequence
data260

Reaffirms
Bermuda
Principles
for
sequence
assemblies
> 2kB257
24 hours
after
generation

Intl.
HapMap
Project
(2003)

256.
257.
258.
259.
260.
261.
262.
263.
264.
265.
266.
267.

SNP and
Haplotype
data264

261

Rapidly265

[Vol. 12:1

User
Restrictio
ns
Citation of
data
producers

Patent
Considerat
ions
Not
specified259

Citation of
data
producers

Not
specified263

Citation of
data
producers

User clickwrap
agreement
prohibits
filing of
patent
applications
on project
data or uses
thereof,
unless unrestricted use
is allowed267

258

262

266

Ft. Lauderdale Principles, supra note 115.
Id.
Id.
See id.
NHGRI 2003 POLICY, supra note 121.
Id.
Id.
See id.
The Int’l HapMap Consortium, supra note 125.
Id.
Id.
Id.; HapMap Agreement, supra note 130.
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ENCODE
Pilot (2003)

Wellcome
Trust Case
Control
Consortiu
m
(WTCCC)
(2006)

Type of
Data

Release
Speed

Various
data types
generated
by the
project268

Deposited
as soon as
data is
verified269

GWA study
data272

Not
specified
273

User
Restrictio
ns
Citation of
data
producers
270

Signed
data access
agreement
Citation of
data
producers;
Security,
transfer
and use
restrictions
274

268.
269.
270.
271.
272.
273.
274.
275.

ENCODE 2003 Pilot Policy, supra note 131.
Id.
Id.
Id.
Publications Policy, supra note 203.
See id.
WTCCC: Access to Genotype Data, supra note 204.
See id.; Publications Policy, supra note 203.

115
Patent
Considerat
ions
NHGRI
encourages
all data
producers to
consider
placing
information
in the public
domain271
None275
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GAIN
(2006)

Type of
Data

Release
Speed

GWA study
data276

Immediate
277

[Vol. 12:1

User
Restrictio
ns
Data use
certificatio
n278
Variablelength
embargo on
publication
and
presentatio
n of data
(generally 9
months),279
Security,
transfer
and use
restrictions

Patent
Considerat
ions
Data users
agree not to
pursue
patents that
would block
access to
data or
conclusions
drawn
directly from
data281

data use
certificatio
n284
Security
and
transfer285
restrictions

Urges users
to avoid
making IP
claims286

280

The Cancer
Genome
Atlas
(TCGA)
(2006)

276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.

Tumor
genomic
and clinical
data282

As rapidly
as
possible283

The GAIN Collaborative Research Group, supra note 153, at 1045.
Id. at 1048.
Id. at 1049.
Id.
Id. at 1046.
Id. at 1050.
Types of Data, supra note 165.
Data Use Certification, supra note 166, at 4.
Id.
Id. at 2–3.
Id.
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NIH GWAS
Policy
(2007)

Type of
Data

Release
Speed

GWA study
data287

Strong
encourage
ment to
submit
data as
soon as
quality
control
procedure
s
completed
288

User
Restrictio
ns
Signed
data use
certificatio
n289
12-month
embargo
expectation
on
publication
and
presentatio
n of
data,290
Citation of
data
producers;
291

Security,
transfer
and use
restrictions
292

287.
288.
289.
290.
291.
292.
293.
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72 Fed. Reg. 49290, 49290 (Aug. 28, 2007).
Id. at 49293.
Id. at 49297.
Id. at 49294.
Id.
72 Fed. Reg. 49290, 49296 (Aug. 28, 2007).
Id.

Patent
Considerat
ions
Patenting of
results
discouraged
293
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Type of
Data

Release
Speed

Intl. SAE
Consortiu
m (2007) 294

Human
genotypic
and
phenotypic
data

12 months
after data
validation

ENCODE +
modENCO
DE (2008)

Various
data types
generated
by the
project295

Deposited
as soon as
data is
verified296

User
Restrictio
ns
Signed
membership
agreement
Up to 9month
embargo on
publication
and
presentatio
n of data
Citation of
data
producers;
Security,
transfer
and use
restrictions
9-month
embargo on
publication
and
presentatio
n of data297
Citation of
data
producers
298

294.
295.
296.
297.
298.
299.

[Vol. 12:1
Patent
Considerat
ions
Data users
agree not to
pursue
patents that
would block
access to
data or
conclusions
drawn
directly from
data

NHGRI
monitoring
of patenting
activity and
potential
consideration of
click-wrap
agreements
(e.g.,
HapMap
Project299)

See supra Part III.E.4.
The ENCODE Project Consortium, supra note 134, at 799.
ENCODE 2003 Pilot Policy, supra note 131.
ENCODE 2008 Policy, supra note 194, at 1.
Id. at 4.
Compare id. at 6–9, with HapMap Agreement, supra note 130.
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B. POLICY DESIGN TRENDS
Even a cursory inspection of Table 1 reveals several points
regarding the evolution of genomics data release policies over
the past two decades. Perhaps most obviously, these policies
have grown more detailed and complex over time. The reasons
for this growth are not difficult to guess. The Bermuda
Principles introduced a sea change to scientific data release.
Despite their groundbreaking significance and lasting
influence, the Bermuda Principles were drafted to address one
specific type of data (genomic sequence reads) generated by a
specific, unique project (the HGP).300 It soon became clear that,
while the spirit and intent of the Bermuda Principles were
attractive to many, the extension of these principles to different
projects and data types required additional explication and, in
some cases, compromise. Below is a summary of the ways in
which policy designers addressed the various policy
considerations associated with the genome commons over this
period.
1. Protection of Human Subject Data
Because the goal of the HGP was to generate a baseline
map of the human genome without regard to the particular
physiological and pathological traits associated with genetic
variation among individuals, the genomic sequence data
generated by the HGP was anonymous and retained no
association with the individual subjects whose DNA was being
sequenced.301 Similar characteristics applied to data generated
by the HapMap Project302 and the SNP Consortium.303 These
data were intended to elucidate non-individualized information
applicable to the human genome generally. Accordingly,
concerns regarding the identifiability of human subjects from
data released to the public, while addressed, were not
300. Policies on Release of Human Genomic Sequence Data, Bermuda
Quality
Sequence,
HUMAN
GENOME
PROJECT
INFORMATION,
http://www.ornl.gov/sci/techresources/Human_Genome/research/bermuda.sht
ml (last visited Oct. 28, 2010).
301. About the Human Genome Project, HUMAN GENOME PROJECT
INFORMATION,
http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml
(last visited Oct. 28, 2010).
302. See What is the HapMap, INTERNATIONAL HAPMAP PROJECT,
http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en (last visited Oct. 28,
2010).
303. Holden, supra note 147.
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paramount in these early projects.
In later projects, and particularly with the commencement
of large-scale GWA studies, concerns with the potential
identification of human subjects grew.304 The genotypic data
generated by a GWA study is not meaningful without the
associated phenotypic data. Because a GWA study often seeks
to associate genotypic information (e.g., particular markers)
with particular disease states, information regarding donor
demographics, disease state and treatment are necessary to
interpret the genotypic findings. The prospect of releasing
clinical and phenotypic data to the public raised concern and
led to the imposition of various policy restrictions on data users’
ability to disclose and transfer data, as well as the controlledaccess mechanisms enabled through repositories such as
dbGaP.305
2. Scientific Advancement and Publication Priority
As discussed above, the more quickly scientific data is
disseminated, the more quickly science will progress.
Conversely, when the release of data is delayed due to the
length of the publication cycle and patenting concerns, it can be
argued that the progress of scientific advancement is retarded,
or at least that it may not achieve its greatest potential. If data
were not withheld until a researcher’s conclusions were
published, but released prior to publication, the months-long
delays associated with the publishing process could be avoided.
Following this line of argument, in an ideal world, maximum
scientific efficiency could be achieved by reducing the delay
between data generation and data release to zero. That is, the
most rapid pace of innovation, discovery of new therapies,
development of new technologies, and understanding of natural
phenomena could be achieved by releasing scientific data to the
community the moment it is generated.
Publication is, however, of crucial importance to scientific
careers. Scientists typically spend months validating and
analyzing their data, formulating hypotheses, re-running
procedures, refining data, and then preparing the manuscript
304. See Toronto Report, supra note 66, at 170.
305. For a general discussion of the protection of human subjects data in
genomic studies, a topic that is beyond the scope of this paper but which has
been extensively addressed in the literature, see for example, ANDREWS ET AL.,
supra note 75, at ch. 13; Crolla, supra note 75, at 241–47.
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of the paper that will present their results to the community.
What rational scientist would wish to give this data away
before he or she has had a chance to analyze it? Why would he
or she enable competitors who have done none of the work to
benefit from the data to the same degree as he or she?306 Even
Merton, who championed the norm of scientific communalism,
did not specify how quickly the sharing of data should occur.307
Thus, a clash of cultures has arisen, with the result being a
heightened focus on the extent to which users of publicly
released data may be restricted in their ability to present or
publish results based on that data. The compromise in several
recent cases has been time-based. That is, the “embargo”
periods in the GAIN Policy, NIH GWAS Policy, and ENCODE
2008 Policy all give users access to data and let them perform
research, but prohibit them from making related presentations
or submitting related papers during the embargo period.308 The
approach taken by private consortia, in contrast, protects data
generator priority by allowing data generators to retain data
privately for a specified period. The trade-offs between these
differing approaches is discussed below.
3. Patent Encumbrances
Patent protection is related to, but distinct from, the issue
of publication priority. As discussed previously, early in the
HGP, following the EST patenting debate, NIH representatives
adopted a position that patent protection is inappropriate for
DNA sequence information.309 This stance, also held by leaders
of the scientific community and international funding agencies,
is reflected in the Bermuda Principles.310 Accordingly, a
number of the data release policies developed by private and
academic consortia, such as those adopted by the International
HapMap Consortium, GAIN, the SNP Consortium, and
International SAE Consortium, take explicit steps to prevent
306. See Eisenberg, Patents and Data-Sharing, supra note 47, at 1021
(“Scientists who share their data promptly and freely may find themselves at a
competitive disadvantage relative to free riders in the race to make and
publish future observations . . . .”).
307. See Margo A. Bagley, Academic Discourse and Proprietary Rights:
Putting Patents in their Proper Place, 47 B.C. L. REV. 217, 227 (2006) (quoting
Robert K. Merton, The Normative Structure of Science, in THE SOCIOLOGY OF
SCIENCE 274–75 (1973)).
308. Supra Table 1.
309. See supra notes 93–94 and accompanying text.
310. Contreras, Prepublication Data Release, supra note 5, at 393.
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the patenting of results generated by their research.311
NHGRI, however, must operate within the constraints of
the Bayh-Dole Act.312 Thus, while NHGRI’s various postBermuda data release policies all acknowledge the
requirements of the Bayh-Dole Act, they demonstrate a general
bias against the placement of patent encumbrances on genomic
data.313 The enforceability, however, of policy provisions that
merely “urge” or “encourage” data generators and users not to
seek patents on inappropriate subject matter is open to some
doubt.314
Lacking a strong policy tool with which to limit expressly
the patenting of genomic information, NHGRI policy makers
have employed rapid pre-publication data release requirements
as a surrogate for achieving the same result. In particular, the
Bermuda Principles and their adoption and reaffirmation by
NHGRI in 1997 and 2003, respectively, ensured that genomic
data from the HGP and other large-scale sequencing projects
would be made publicly-available before data generators had
an opportunity to file patent applications covering any
“inventions” arising from that data and in a manner that
ensured its availability as prior art against third party patent
filings at the earliest possible date.315
When publication priority issues began to emerge with the
movement toward GWAS and other studies involving
phenotypic data components, the publication embargo was
offered as a solution that both protected the publication
interests of data generators, but still ensured the early release
of data and, consequently, the patent-frustrating effects
produced by the rapid pre-publication data release principles
espoused by the Bermuda Principles.

311. Supra Table 1.
312. NHGRI 1996 POLICY, supra note 107.
313. See ENCODE Pilot Policy, supra note 131; NHGRI 1996 POLICY, supra
note 107 and accompanying text; NIH GWAS Policy, supra note 172.
314. See Rai & Eisenberg, supra note 106, at 309.
315. Interestingly, Rebecca Eisenberg suggests that, in some cases, the
early release of experimental data may actually encourage more patent filings
by third parties who are thereby enabled to combine public data with
proprietary improvements and patent the combination thereof. See Eisenberg,
supra note 47, at 1026.
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V. CONCLUSION
The twenty-year evolution of the genome commons
illustrates the ways in which the distinct policy objectives of
the relevant stakeholder communities have interacted over
time to shape the formal and informal rules that govern the
commons. Although governmental agencies played a significant
role in the ongoing development of the policies governing the
genome commons, other stakeholder groups including data
generators, data users, and the public have strongly influenced
the direction that these rules have taken. While the
groundbreaking Bermuda Principles were straightforward in
their implementation and effect, subsequent policies reflect an
increased complexity that has arisen from the need to balance
the competing and sometimes contradictory interests of these
stakeholder groups.316
The policy considerations described in this paper are by no
means unique to the genome commons. Issues relating to the
advancement of science, the appropriate level of patent
protection for scientific discoveries, and value-maximizing
rewards for researchers are pervasive in many fields of study.
Thus, the lessons learned, and the compromises reached, by the
designers of the genome commons can inform the discussion
and analysis of scientific commons in a variety of fields.
Moreover, as the genome commons continues to mature and
expand into areas such as proteomics and metabolomics, the
policies in existence today will likewise evolve. It is hoped that
policy makers considering the design of new commons in these
areas will look to the past to understand the complex
compromises and rationales behind the policies that flowed
from the Bermuda Principles, the legacy of which is likely to
remain influential for years to come.

316. For a discussion of the use of timing or “latency” variables as effective
means for mediating among these competing stakeholder interests, see
generally Contreras, Data Sharing, supra note 5.
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APPENDIX – GLOSSARY OF TERMS
CRP—Community Resource Project (description of a type
of research project developed at the Ft. Lauderdale data release
meeting)
DAC—Data Access Committee
dbGaP—Database of Genotypes and Phenotypes (database
administered by the NIH’s National Library of Medicine)
DDBJDNA—Databank of Japan (leading international
DNA sequence repository)
DOE—U.S. Department of Energy
EMBL—European Molecular Biology Laboratory (leading
European genomics research center and host of a large DNA
sequence repository in Hinxton, England)
ENCODE—Encyclopedia of DNA Elements (an NIHfunded research project seeking to identify functional elements
of the human genome)
EST—Expressed Sequence Tag (a short fragment of DNA)
GAIN—Genetic Association Information Network (a
consortium formed to conduct GWA studies on six common
human diseases)
GWAS—Genome-Wide Association Study (a study that
seeks genetic markers for specified physiological or pathological
traits)
GenBank—A publicly-accessible database of genetic
sequences maintained by NCBI
HGP—Human Genome Project (the U.S.-led international
project to sequence the human genome)
HIPAA—Health Insurance Portability and Accountability
Act (U.S. legislation governing, among other things, privacy of
patient healthcare data)
HUGO—Human Genome Organisation (an international,
policy-oriented group formed near the beginning of the HGP)
Kb—Kilobase (unit of measurement equal to 1,000 DNA
base pairs)
MRC—UK Medical Research Council (principal medical
funding agency in Britain)
NAS—National Academy of Sciences (non-governmental
agency that advises the U.S. government on scientific matters)
NCBI—National Center for Biotechnology Information
(NIH center that operates bioinformatics resources such as
GenBank)
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NCI—National Cancer Institute (NIH institute dedicated
to cancer research, including cancer genomics)
NHGRI—National Human Genome Research Institute (the
principal U.S. funding agency for genomic research and one of
the NIH institutes)
NIH—National Institutes of Health (the principal U.S.
funding agency for biomedical research, comprised of numerous
different institutes)
NRC—National Research Council of the U.S. National
Academy of Sciences
SNP—Single-Nucleotide Polymorphism (a “marker” in the
genetic code)
TCGA—The Cancer Genome Atlas (an NIH-funded pilot
project relating to cancer genomics)
WTCCC—Wellcome Trust Case Control Consortium (a
large-scale UK-based GWA study)

